id	sid	tid	token	lemma	pos
ajrhss-1518	1	1	american	american	PROPN
ajrhss-1518	1	2	journal	journal	PROPN
ajrhss-1518	1	3	of	of	ADP
ajrhss-1518	1	4	research	research	NOUN
ajrhss-1518	1	5	in	in	ADP
ajrhss-1518	1	6	humanities	humanity	NOUN
ajrhss-1518	1	7	and	and	CCONJ
ajrhss-1518	1	8	social	social	ADJ
ajrhss-1518	1	9	sciences	science	NOUN
ajrhss-1518	1	10	issn	issn	PROPN
ajrhss-1518	1	11	(	(	PUNCT
ajrhss-1518	1	12	e	e	NOUN
ajrhss-1518	1	13	):	):	PUNCT
ajrhss-1518	1	14	2832	2832	NUM
ajrhss-1518	1	15	-	-	SYM
ajrhss-1518	1	16	8019	8019	NUM
ajrhss-1518	1	17	volume	volume	NOUN
ajrhss-1518	1	18	18	18	NUM
ajrhss-1518	1	19	,	,	PUNCT
ajrhss-1518	1	20	|	|	ADV
ajrhss-1518	1	21	november	november	PROPN
ajrhss-1518	1	22	,	,	PUNCT
ajrhss-1518	1	23	2023	2023	NUM
ajrhss-1518	1	24	p	p	NOUN
ajrhss-1518	1	25	a	a	PRON
ajrhss-1518	1	26	g	g	NOUN
ajrhss-1518	1	27	e	e	NOUN
ajrhss-1518	1	28	|	|	ADV
ajrhss-1518	1	29	136	136	NUM
ajrhss-1518	1	30	www.americanjournal.org	www.americanjournal.org	NOUN
ajrhss-1518	1	31	a	a	DET
ajrhss-1518	1	32	new	new	ADJ
ajrhss-1518	1	33	approach	approach	NOUN
ajrhss-1518	1	34	to	to	ADP
ajrhss-1518	1	35	etiotropic	etiotropic	NOUN
ajrhss-1518	1	36	therapy	therapy	NOUN
ajrhss-1518	1	37	arvi	arvi	NOUN
ajrhss-1518	1	38	in	in	ADP
ajrhss-1518	1	39	children	child	NOUN
ajrhss-1518	1	40	mukhtorova	mukhtorova	PROPN
ajrhss-1518	1	41	sh.a	sh.a	X
ajrhss-1518	1	42	.	.	PUNCT
ajrhss-1518	2	1	bukhara	bukhara	PROPN
ajrhss-1518	2	2	state	state	PROPN
ajrhss-1518	2	3	medical	medical	PROPN
ajrhss-1518	2	4	institute	institute	PROPN
ajrhss-1518	2	5	named	name	VERB
ajrhss-1518	2	6	after	after	ADP
ajrhss-1518	2	7	abu	abu	PROPN
ajrhss-1518	2	8	ali	ali	PROPN
ajrhss-1518	2	9	ibn	ibn	PROPN
ajrhss-1518	2	10	sino	sino	ADJ
ajrhss-1518	2	11	,	,	PUNCT
ajrhss-1518	2	12	uzbekistan	uzbekistan	PROPN
ajrhss-1518	2	13	,	,	PUNCT
ajrhss-1518	2	14	bukhara	bukhara	PROPN
ajrhss-1518	2	15	,	,	PUNCT
ajrhss-1518	2	16	st	st	PROPN
ajrhss-1518	2	17	.	.	PROPN
ajrhss-1518	2	18	a.	a.	NOUN
ajrhss-1518	2	19	navoi	navoi	PROPN
ajrhss-1518	2	20	.	.	PUNCT
ajrhss-1518	3	1	1	1	NUM
ajrhss-1518	3	2	tel	tel	PROPN
ajrhss-1518	3	3	:	:	PUNCT
ajrhss-1518	3	4	+998	+998	NUM
ajrhss-1518	3	5	(	(	PUNCT
ajrhss-1518	3	6	65	65	NUM
ajrhss-1518	3	7	)	)	PUNCT
ajrhss-1518	3	8	223	223	NUM
ajrhss-1518	3	9	-	-	SYM
ajrhss-1518	3	10	00	00	NUM
ajrhss-1518	3	11	-	-	SYM
ajrhss-1518	3	12	50	50	NUM
ajrhss-1518	3	13	e	e	NOUN
ajrhss-1518	3	14	-	-	NOUN
ajrhss-1518	3	15	mail	mail	NOUN
ajrhss-1518	3	16	:	:	PUNCT
ajrhss-1518	3	17	info@bsmi.uz	info@bsmi.uz	PROPN
ajrhss-1518	3	18	https://orcid.org/0000-0002-1522-75370	https://orcid.org/0000-0002-1522-75370	PROPN
ajrhss-1518	3	19	a	a	DET
ajrhss-1518	3	20	b	b	PROPN
ajrhss-1518	3	21	s	s	ADP
ajrhss-1518	3	22	t	t	PROPN
ajrhss-1518	3	23	r	r	NOUN
ajrhss-1518	3	24	a	a	DET
ajrhss-1518	3	25	c	c	NOUN
ajrhss-1518	3	26	t	t	NOUN
ajrhss-1518	3	27	k	k	X
ajrhss-1518	3	28	e	e	PROPN
ajrhss-1518	3	29	y	y	PROPN
ajrhss-1518	3	30	w	w	NOUN
ajrhss-1518	3	31	o	o	NOUN
ajrhss-1518	3	32	r	r	NOUN
ajrhss-1518	3	33	d	d	NOUN
ajrhss-1518	3	34	s	s	NOUN
ajrhss-1518	3	35	aim	aim	NOUN
ajrhss-1518	3	36	.	.	PUNCT
ajrhss-1518	4	1	confirmation	confirmation	NOUN
ajrhss-1518	4	2	of	of	ADP
ajrhss-1518	4	3	the	the	DET
ajrhss-1518	4	4	efficacy	efficacy	NOUN
ajrhss-1518	4	5	and	and	CCONJ
ajrhss-1518	4	6	safety	safety	NOUN
ajrhss-1518	4	7	of	of	ADP
ajrhss-1518	4	8	the	the	DET
ajrhss-1518	4	9	drug	drug	NOUN
ajrhss-1518	4	10	riamilovir	riamilovir	PROPN
ajrhss-1518	4	11	(	(	PUNCT
ajrhss-1518	4	12	triazavirin	triazavirin	PROPN
ajrhss-1518	4	13	®	®	PROPN
ajrhss-1518	4	14	)	)	PUNCT
ajrhss-1518	4	15	,	,	PUNCT
ajrhss-1518	4	16	100	100	NUM
ajrhss-1518	4	17	mg	mg	ADJ
ajrhss-1518	4	18	capsules	capsule	NOUN
ajrhss-1518	4	19	,	,	PUNCT
ajrhss-1518	4	20	in	in	ADP
ajrhss-1518	4	21	children	child	NOUN
ajrhss-1518	4	22	aged	age	VERB
ajrhss-1518	4	23	12–17	12–17	NUM
ajrhss-1518	4	24	years	year	NOUN
ajrhss-1518	4	25	with	with	ADP
ajrhss-1518	4	26	the	the	DET
ajrhss-1518	4	27	diagnosis	diagnosis	NOUN
ajrhss-1518	4	28	of	of	ADP
ajrhss-1518	4	29	acute	acute	ADJ
ajrhss-1518	4	30	viral	viral	ADJ
ajrhss-1518	4	31	respiratory	respiratory	ADJ
ajrhss-1518	4	32	infection	infection	NOUN
ajrhss-1518	4	33	(	(	PUNCT
ajrhss-1518	4	34	arvi	arvi	PROPN
ajrhss-1518	4	35	)	)	PUNCT
ajrhss-1518	4	36	.	.	PUNCT
ajrhss-1518	5	1	materials	material	NOUN
ajrhss-1518	5	2	and	and	CCONJ
ajrhss-1518	5	3	methods	method	NOUN
ajrhss-1518	5	4	.	.	PUNCT
ajrhss-1518	6	1	the	the	DET
ajrhss-1518	6	2	multicenter	multicenter	ADJ
ajrhss-1518	6	3	study	study	NOUN
ajrhss-1518	6	4	included	include	VERB
ajrhss-1518	6	5	269	269	NUM
ajrhss-1518	6	6	patients	patient	NOUN
ajrhss-1518	6	7	diagnosed	diagnose	VERB
ajrhss-1518	6	8	with	with	ADP
ajrhss-1518	6	9	acute	acute	ADJ
ajrhss-1518	6	10	viral	viral	ADJ
ajrhss-1518	6	11	respiratory	respiratory	ADJ
ajrhss-1518	6	12	infection	infection	NOUN
ajrhss-1518	6	13	(	(	PUNCT
ajrhss-1518	6	14	icd-10	icd-10	DET
ajrhss-1518	6	15	code	code	NOUN
ajrhss-1518	6	16	:	:	PUNCT
ajrhss-1518	6	17	j00	j00	PROPN
ajrhss-1518	6	18	,	,	PUNCT
ajrhss-1518	6	19	j02	j02	PROPN
ajrhss-1518	6	20	,	,	PUNCT
ajrhss-1518	6	21	j02.9	j02.9	PROPN
ajrhss-1518	6	22	,	,	PUNCT
ajrhss-1518	6	23	j04	j04	NOUN
ajrhss-1518	6	24	,	,	PUNCT
ajrhss-1518	6	25	j04.0	j04.0	PROPN
ajrhss-1518	6	26	,	,	PUNCT
ajrhss-1518	6	27	j04.1	j04.1	NOUN
ajrhss-1518	6	28	,	,	PUNCT
ajrhss-1518	6	29	j04.2	j04.2	PROPN
ajrhss-1518	6	30	,	,	PUNCT
ajrhss-1518	6	31	j06	j06	PROPN
ajrhss-1518	6	32	,	,	PUNCT
ajrhss-1518	6	33	j06.0	j06.0	PROPN
ajrhss-1518	6	34	,	,	PUNCT
ajrhss-1518	6	35	j06.9	j06.9	PROPN
ajrhss-1518	6	36	)	)	PUNCT
ajrhss-1518	6	37	in	in	ADP
ajrhss-1518	6	38	the	the	DET
ajrhss-1518	6	39	presence	presence	NOUN
ajrhss-1518	6	40	of	of	ADP
ajrhss-1518	6	41	clinical	clinical	ADJ
ajrhss-1518	6	42	manifestations	manifestation	NOUN
ajrhss-1518	6	43	and	and	CCONJ
ajrhss-1518	6	44	confirmation	confirmation	NOUN
ajrhss-1518	6	45	of	of	ADP
ajrhss-1518	6	46	the	the	DET
ajrhss-1518	6	47	etiology	etiology	NOUN
ajrhss-1518	6	48	of	of	ADP
ajrhss-1518	6	49	the	the	DET
ajrhss-1518	6	50	disease	disease	NOUN
ajrhss-1518	6	51	by	by	ADP
ajrhss-1518	6	52	laboratory	laboratory	NOUN
ajrhss-1518	6	53	tests	test	NOUN
ajrhss-1518	6	54	(	(	PUNCT
ajrhss-1518	6	55	pcr	pcr	NOUN
ajrhss-1518	6	56	method	method	NOUN
ajrhss-1518	6	57	)	)	PUNCT
ajrhss-1518	6	58	.	.	PUNCT
ajrhss-1518	7	1	patients	patient	NOUN
ajrhss-1518	7	2	were	be	AUX
ajrhss-1518	7	3	included	include	VERB
ajrhss-1518	7	4	in	in	ADP
ajrhss-1518	7	5	the	the	DET
ajrhss-1518	7	6	study	study	NOUN
ajrhss-1518	7	7	after	after	ADP
ajrhss-1518	7	8	one	one	NUM
ajrhss-1518	7	9	of	of	ADP
ajrhss-1518	7	10	the	the	DET
ajrhss-1518	7	11	patient	patient	NOUN
ajrhss-1518	7	12	's	's	PART
ajrhss-1518	7	13	parents	parent	NOUN
ajrhss-1518	7	14	/	/	SYM
ajrhss-1518	7	15	adoptive	adoptive	ADJ
ajrhss-1518	7	16	parents	parent	NOUN
ajrhss-1518	7	17	and	and	CCONJ
ajrhss-1518	7	18	the	the	DET
ajrhss-1518	7	19	patient	patient	NOUN
ajrhss-1518	7	20	signed	sign	VERB
ajrhss-1518	7	21	an	an	DET
ajrhss-1518	7	22	informed	informed	ADJ
ajrhss-1518	7	23	consent	consent	NOUN
ajrhss-1518	7	24	to	to	PART
ajrhss-1518	7	25	participate	participate	VERB
ajrhss-1518	7	26	in	in	ADP
ajrhss-1518	7	27	the	the	DET
ajrhss-1518	7	28	study	study	NOUN
ajrhss-1518	7	29	.	.	PUNCT
ajrhss-1518	8	1	the	the	DET
ajrhss-1518	8	2	interval	interval	NOUN
ajrhss-1518	8	3	between	between	ADP
ajrhss-1518	8	4	the	the	DET
ajrhss-1518	8	5	appearance	appearance	NOUN
ajrhss-1518	8	6	of	of	ADP
ajrhss-1518	8	7	the	the	DET
ajrhss-1518	8	8	first	first	ADJ
ajrhss-1518	8	9	symptoms	symptom	NOUN
ajrhss-1518	8	10	of	of	ADP
ajrhss-1518	8	11	the	the	DET
ajrhss-1518	8	12	disease	disease	NOUN
ajrhss-1518	8	13	and	and	CCONJ
ajrhss-1518	8	14	the	the	DET
ajrhss-1518	8	15	inclusion	inclusion	NOUN
ajrhss-1518	8	16	of	of	ADP
ajrhss-1518	8	17	the	the	DET
ajrhss-1518	8	18	patient	patient	NOUN
ajrhss-1518	8	19	in	in	ADP
ajrhss-1518	8	20	the	the	DET
ajrhss-1518	8	21	study	study	NOUN
ajrhss-1518	8	22	did	do	AUX
ajrhss-1518	8	23	not	not	PART
ajrhss-1518	8	24	exceed	exceed	VERB
ajrhss-1518	8	25	36	36	NUM
ajrhss-1518	8	26	hours	hour	NOUN
ajrhss-1518	8	27	.	.	PUNCT
ajrhss-1518	9	1	results	result	NOUN
ajrhss-1518	9	2	.	.	PUNCT
ajrhss-1518	10	1	as	as	ADP
ajrhss-1518	10	2	a	a	DET
ajrhss-1518	10	3	result	result	NOUN
ajrhss-1518	10	4	of	of	ADP
ajrhss-1518	10	5	a	a	DET
ajrhss-1518	10	6	clinical	clinical	ADJ
ajrhss-1518	10	7	study	study	NOUN
ajrhss-1518	10	8	,	,	PUNCT
ajrhss-1518	10	9	the	the	DET
ajrhss-1518	10	10	efficacy	efficacy	NOUN
ajrhss-1518	10	11	and	and	CCONJ
ajrhss-1518	10	12	safety	safety	NOUN
ajrhss-1518	10	13	of	of	ADP
ajrhss-1518	10	14	treatment	treatment	NOUN
ajrhss-1518	10	15	with	with	ADP
ajrhss-1518	10	16	riamilovir	riamilovir	PROPN
ajrhss-1518	10	17	(	(	PUNCT
ajrhss-1518	10	18	triazavirin	triazavirin	PROPN
ajrhss-1518	10	19	®	®	PROPN
ajrhss-1518	10	20	)	)	PUNCT
ajrhss-1518	10	21	in	in	ADP
ajrhss-1518	10	22	sick	sick	ADJ
ajrhss-1518	10	23	children	child	NOUN
ajrhss-1518	10	24	aged	age	VERB
ajrhss-1518	10	25	12–17	12–17	NUM
ajrhss-1518	10	26	years	year	NOUN
ajrhss-1518	10	27	with	with	ADP
ajrhss-1518	10	28	a	a	DET
ajrhss-1518	10	29	diagnosis	diagnosis	NOUN
ajrhss-1518	10	30	of	of	ADP
ajrhss-1518	10	31	arvi	arvi	NOUN
ajrhss-1518	10	32	was	be	AUX
ajrhss-1518	10	33	shown	show	VERB
ajrhss-1518	10	34	.	.	PUNCT
ajrhss-1518	11	1	a	a	DET
ajrhss-1518	11	2	decrease	decrease	NOUN
ajrhss-1518	11	3	in	in	ADP
ajrhss-1518	11	4	the	the	DET
ajrhss-1518	11	5	duration	duration	NOUN
ajrhss-1518	11	6	of	of	ADP
ajrhss-1518	11	7	the	the	DET
ajrhss-1518	11	8	disease	disease	NOUN
ajrhss-1518	11	9	was	be	AUX
ajrhss-1518	11	10	shown	show	VERB
ajrhss-1518	11	11	when	when	SCONJ
ajrhss-1518	11	12	using	use	VERB
ajrhss-1518	11	13	the	the	DET
ajrhss-1518	11	14	drug	drug	NOUN
ajrhss-1518	11	15	riamilovir	riamilovir	PROPN
ajrhss-1518	11	16	(	(	PUNCT
ajrhss-1518	11	17	triazavirin	triazavirin	PROPN
ajrhss-1518	11	18	®	®	PROPN
ajrhss-1518	11	19	)	)	PUNCT
ajrhss-1518	11	20	compared	compare	VERB
ajrhss-1518	11	21	with	with	ADP
ajrhss-1518	11	22	the	the	DET
ajrhss-1518	11	23	control	control	NOUN
ajrhss-1518	11	24	group	group	NOUN
ajrhss-1518	11	25	.	.	PUNCT
ajrhss-1518	12	1	no	no	DET
ajrhss-1518	12	2	serious	serious	ADJ
ajrhss-1518	12	3	adverse	adverse	ADJ
ajrhss-1518	12	4	events	event	NOUN
ajrhss-1518	12	5	were	be	AUX
ajrhss-1518	12	6	detected	detect	VERB
ajrhss-1518	12	7	during	during	ADP
ajrhss-1518	12	8	the	the	DET
ajrhss-1518	12	9	study	study	NOUN
ajrhss-1518	12	10	.	.	PUNCT
ajrhss-1518	13	1	conclusion	conclusion	NOUN
ajrhss-1518	13	2	.	.	PUNCT
ajrhss-1518	14	1	as	as	ADP
ajrhss-1518	14	2	a	a	DET
ajrhss-1518	14	3	result	result	NOUN
ajrhss-1518	14	4	of	of	ADP
ajrhss-1518	14	5	the	the	DET
ajrhss-1518	14	6	conducted	conduct	VERB
ajrhss-1518	14	7	clinical	clinical	ADJ
ajrhss-1518	14	8	study	study	NOUN
ajrhss-1518	14	9	,	,	PUNCT
ajrhss-1518	14	10	the	the	DET
ajrhss-1518	14	11	high	high	ADJ
ajrhss-1518	14	12	efficacy	efficacy	NOUN
ajrhss-1518	14	13	,	,	PUNCT
ajrhss-1518	14	14	safety	safety	NOUN
ajrhss-1518	14	15	and	and	CCONJ
ajrhss-1518	14	16	good	good	ADJ
ajrhss-1518	14	17	tolerability	tolerability	NOUN
ajrhss-1518	14	18	of	of	ADP
ajrhss-1518	14	19	the	the	DET
ajrhss-1518	14	20	drug	drug	NOUN
ajrhss-1518	14	21	riamilovir	riamilovir	PRON
ajrhss-1518	14	22	in	in	ADP
ajrhss-1518	14	23	the	the	DET
ajrhss-1518	14	24	treatment	treatment	NOUN
ajrhss-1518	14	25	of	of	ADP
ajrhss-1518	14	26	children	child	NOUN
ajrhss-1518	14	27	aged	age	VERB
ajrhss-1518	14	28	12–17	12–17	NUM
ajrhss-1518	14	29	years	year	NOUN
ajrhss-1518	14	30	with	with	ADP
ajrhss-1518	14	31	a	a	DET
ajrhss-1518	14	32	diagnosis	diagnosis	NOUN
ajrhss-1518	14	33	of	of	ADP
ajrhss-1518	14	34	arvi	arvi	NOUN
ajrhss-1518	14	35	was	be	AUX
ajrhss-1518	14	36	established	establish	VERB
ajrhss-1518	14	37	.	.	PUNCT
ajrhss-1518	15	1	it	it	PRON
ajrhss-1518	15	2	is	be	AUX
ajrhss-1518	15	3	recommended	recommend	VERB
ajrhss-1518	15	4	to	to	PART
ajrhss-1518	15	5	use	use	VERB
ajrhss-1518	15	6	the	the	DET
ajrhss-1518	15	7	drug	drug	NOUN
ajrhss-1518	15	8	riamilovir	riamilovir	PRON
ajrhss-1518	15	9	in	in	ADP
ajrhss-1518	15	10	clinical	clinical	ADJ
ajrhss-1518	15	11	practice	practice	NOUN
ajrhss-1518	15	12	as	as	ADP
ajrhss-1518	15	13	an	an	DET
ajrhss-1518	15	14	etiotropic	etiotropic	NOUN
ajrhss-1518	15	15	therapy	therapy	NOUN
ajrhss-1518	15	16	in	in	ADP
ajrhss-1518	15	17	children	child	NOUN
ajrhss-1518	15	18	aged	age	VERB
ajrhss-1518	15	19	12–17	12–17	NUM
ajrhss-1518	15	20	years	year	NOUN
ajrhss-1518	15	21	with	with	ADP
ajrhss-1518	15	22	a	a	DET
ajrhss-1518	15	23	diagnosis	diagnosis	NOUN
ajrhss-1518	15	24	of	of	ADP
ajrhss-1518	15	25	arvi	arvi	NOUN
ajrhss-1518	15	26	due	due	ADP
ajrhss-1518	15	27	to	to	ADP
ajrhss-1518	15	28	its	its	PRON
ajrhss-1518	15	29	high	high	ADJ
ajrhss-1518	15	30	efficacy	efficacy	NOUN
ajrhss-1518	15	31	and	and	CCONJ
ajrhss-1518	15	32	safety	safety	NOUN
ajrhss-1518	15	33	.	.	PUNCT
ajrhss-1518	16	1	acute	acute	ADJ
ajrhss-1518	16	2	viral	viral	ADJ
ajrhss-1518	16	3	respiratory	respiratory	ADJ
ajrhss-1518	16	4	infection	infection	NOUN
ajrhss-1518	16	5	,	,	PUNCT
ajrhss-1518	16	6	arvi	arvi	NOUN
ajrhss-1518	16	7	,	,	PUNCT
ajrhss-1518	16	8	children	child	NOUN
ajrhss-1518	16	9	,	,	PUNCT
ajrhss-1518	16	10	riamilovir	riamilovir	PRON
ajrhss-1518	16	11	,	,	PUNCT
ajrhss-1518	16	12	etiotropic	etiotropic	ADJ
ajrhss-1518	16	13	antiviral	antiviral	ADJ
ajrhss-1518	16	14	therapy	therapy	NOUN
ajrhss-1518	16	15	.	.	PUNCT
ajrhss-1518	17	1	introduction	introduction	NOUN
ajrhss-1518	17	2	in	in	ADP
ajrhss-1518	17	3	clinical	clinical	ADJ
ajrhss-1518	17	4	practice	practice	NOUN
ajrhss-1518	17	5	,	,	PUNCT
ajrhss-1518	17	6	there	there	PRON
ajrhss-1518	17	7	is	be	VERB
ajrhss-1518	17	8	a	a	DET
ajrhss-1518	17	9	collective	collective	ADJ
ajrhss-1518	17	10	concept	concept	NOUN
ajrhss-1518	17	11	of	of	ADP
ajrhss-1518	17	12	“	"	PUNCT
ajrhss-1518	17	13	acute	acute	ADJ
ajrhss-1518	17	14	respiratory	respiratory	ADJ
ajrhss-1518	17	15	viral	viral	ADJ
ajrhss-1518	17	16	infections	infection	NOUN
ajrhss-1518	17	17	”	"	PUNCT
ajrhss-1518	17	18	(	(	PUNCT
ajrhss-1518	17	19	arvi	arvi	NOUN
ajrhss-1518	17	20	)	)	PUNCT
ajrhss-1518	17	21	,	,	PUNCT
ajrhss-1518	17	22	which	which	PRON
ajrhss-1518	17	23	implies	imply	VERB
ajrhss-1518	17	24	a	a	DET
ajrhss-1518	17	25	number	number	NOUN
ajrhss-1518	17	26	of	of	ADP
ajrhss-1518	17	27	diseases	disease	NOUN
ajrhss-1518	17	28	mainly	mainly	ADV
ajrhss-1518	17	29	of	of	ADP
ajrhss-1518	17	30	the	the	DET
ajrhss-1518	17	31	upper	upper	ADJ
ajrhss-1518	17	32	respiratory	respiratory	ADJ
ajrhss-1518	17	33	tract	tract	NOUN
ajrhss-1518	17	34	with	with	ADP
ajrhss-1518	17	35	manifestations	manifestation	NOUN
ajrhss-1518	17	36	of	of	ADP
ajrhss-1518	17	37	catarrhalinflammatory	catarrhalinflammatory	ADJ
ajrhss-1518	17	38	syndrome	syndrome	NOUN
ajrhss-1518	17	39	and	and	CCONJ
ajrhss-1518	17	40	intoxication	intoxication	NOUN
ajrhss-1518	17	41	.	.	PUNCT
ajrhss-1518	18	1	the	the	DET
ajrhss-1518	18	2	spectrum	spectrum	NOUN
ajrhss-1518	18	3	of	of	ADP
ajrhss-1518	18	4	arvi	arvi	NOUN
ajrhss-1518	18	5	pathogens	pathogen	NOUN
ajrhss-1518	18	6	that	that	PRON
ajrhss-1518	18	7	annually	annually	ADV
ajrhss-1518	18	8	cause	cause	VERB
ajrhss-1518	18	9	epidemics	epidemic	NOUN
ajrhss-1518	18	10	in	in	ADP
ajrhss-1518	18	11	the	the	DET
ajrhss-1518	18	12	world	world	NOUN
ajrhss-1518	18	13	in	in	ADP
ajrhss-1518	18	14	the	the	DET
ajrhss-1518	18	15	autumn	autumn	NOUN
ajrhss-1518	18	16	-	-	PUNCT
ajrhss-1518	18	17	winter	winter	NOUN
ajrhss-1518	18	18	period	period	NOUN
ajrhss-1518	18	19	includes	include	VERB
ajrhss-1518	18	20	rna	rna	NOUN
ajrhss-1518	18	21	and	and	CCONJ
ajrhss-1518	18	22	dna	dna	PROPN
ajrhss-1518	18	23	viruses	virus	NOUN
ajrhss-1518	18	24	of	of	ADP
ajrhss-1518	18	25	various	various	ADJ
ajrhss-1518	18	26	families	family	NOUN
ajrhss-1518	18	27	,	,	PUNCT
ajrhss-1518	18	28	most	most	ADV
ajrhss-1518	18	29	often	often	ADV
ajrhss-1518	18	30	rhino-	rhino-	ADJ
ajrhss-1518	18	31	,	,	PUNCT
ajrhss-1518	18	32	boca-	boca-	ADV
ajrhss-1518	18	33	,	,	PUNCT
ajrhss-1518	18	34	adeno-	adeno-	X
ajrhss-1518	18	35	,	,	PUNCT
ajrhss-1518	18	36	metapneumo-	metapneumo-	PROPN
ajrhss-1518	18	37	,	,	PUNCT
ajrhss-1518	18	38	coronaviruses	coronaviruse	NOUN
ajrhss-1518	18	39	,	,	PUNCT
ajrhss-1518	18	40	parainfluenza	parainfluenza	ADJ
ajrhss-1518	18	41	viruses	virus	NOUN
ajrhss-1518	18	42	,	,	PUNCT
ajrhss-1518	18	43	and	and	CCONJ
ajrhss-1518	18	44	respiratory	respiratory	ADJ
ajrhss-1518	18	45	syncytial	syncytial	ADJ
ajrhss-1518	18	46	viruses	virus	NOUN
ajrhss-1518	18	47	.	.	PUNCT
ajrhss-1518	19	1	it	it	PRON
ajrhss-1518	19	2	has	have	AUX
ajrhss-1518	19	3	been	be	AUX
ajrhss-1518	19	4	noted	note	VERB
ajrhss-1518	19	5	that	that	SCONJ
ajrhss-1518	19	6	some	some	DET
ajrhss-1518	19	7	rhino-	rhino-	ADJ
ajrhss-1518	19	8	,	,	PUNCT
ajrhss-1518	19	9	adenoand	adenoand	NOUN
ajrhss-1518	19	10	enteroviruses	enterovirus	NOUN
ajrhss-1518	19	11	can	can	AUX
ajrhss-1518	19	12	induce	induce	VERB
ajrhss-1518	19	13	stable	stable	ADJ
ajrhss-1518	19	14	immunity	immunity	NOUN
ajrhss-1518	19	15	,	,	PUNCT
ajrhss-1518	19	16	which	which	PRON
ajrhss-1518	19	17	is	be	AUX
ajrhss-1518	19	18	type	type	NOUN
ajrhss-1518	19	19	-	-	PUNCT
ajrhss-1518	19	20	specific	specific	NOUN
ajrhss-1518	19	21	,	,	PUNCT
ajrhss-1518	19	22	which	which	PRON
ajrhss-1518	19	23	does	do	AUX
ajrhss-1518	19	24	not	not	PART
ajrhss-1518	19	25	exclude	exclude	VERB
ajrhss-1518	19	26	infection	infection	NOUN
ajrhss-1518	19	27	with	with	ADP
ajrhss-1518	19	28	other	other	ADJ
ajrhss-1518	19	29	serotypes	serotype	NOUN
ajrhss-1518	19	30	of	of	ADP
ajrhss-1518	19	31	viruses	virus	NOUN
ajrhss-1518	19	32	.	.	PUNCT
ajrhss-1518	20	1	and	and	CCONJ
ajrhss-1518	20	2	mailto:info@bsmi.uz	mailto:info@bsmi.uz	PROPN
ajrhss-1518	20	3	american	american	PROPN
ajrhss-1518	20	4	journal	journal	PROPN
ajrhss-1518	20	5	of	of	ADP
ajrhss-1518	20	6	research	research	NOUN
ajrhss-1518	20	7	in	in	ADP
ajrhss-1518	20	8	humanities	humanity	NOUN
ajrhss-1518	20	9	and	and	CCONJ
ajrhss-1518	20	10	social	social	ADJ
ajrhss-1518	20	11	sciences	science	NOUN
ajrhss-1518	20	12	volume	volume	NOUN
ajrhss-1518	20	13	18	18	NUM
ajrhss-1518	20	14	nov	nov	PROPN
ajrhss-1518	20	15	.	.	PROPN
ajrhss-1518	20	16	,	,	PUNCT
ajrhss-1518	20	17	2023	2023	NUM
ajrhss-1518	20	18	p	p	NOUN
ajrhss-1518	20	19	a	a	DET
ajrhss-1518	20	20	g	g	NOUN
ajrhss-1518	20	21	e	e	NOUN
ajrhss-1518	20	22	|	|	NOUN
ajrhss-1518	20	23	137	137	NUM
ajrhss-1518	20	24	www.americanjournal.org	www.americanjournal.org	NOUN
ajrhss-1518	20	25	in	in	ADP
ajrhss-1518	20	26	case	case	NOUN
ajrhss-1518	20	27	of	of	ADP
ajrhss-1518	20	28	infection	infection	NOUN
ajrhss-1518	20	29	with	with	ADP
ajrhss-1518	20	30	parainfluenza	parainfluenza	ADJ
ajrhss-1518	20	31	viruses	virus	NOUN
ajrhss-1518	20	32	,	,	PUNCT
ajrhss-1518	20	33	respiratory	respiratory	ADJ
ajrhss-1518	20	34	syncytial	syncytial	ADJ
ajrhss-1518	20	35	viruses	virus	NOUN
ajrhss-1518	20	36	,	,	PUNCT
ajrhss-1518	20	37	coronaviruses	coronaviruse	NOUN
ajrhss-1518	20	38	,	,	PUNCT
ajrhss-1518	20	39	stable	stable	ADJ
ajrhss-1518	20	40	immunity	immunity	NOUN
ajrhss-1518	20	41	is	be	AUX
ajrhss-1518	20	42	not	not	PART
ajrhss-1518	20	43	formed	form	VERB
ajrhss-1518	20	44	[	[	X
ajrhss-1518	20	45	1	1	NUM
ajrhss-1518	20	46	]	]	PUNCT
ajrhss-1518	20	47	.	.	PUNCT
ajrhss-1518	21	1	the	the	DET
ajrhss-1518	21	2	share	share	NOUN
ajrhss-1518	21	3	of	of	ADP
ajrhss-1518	21	4	arvi	arvi	NOUN
ajrhss-1518	21	5	in	in	ADP
ajrhss-1518	21	6	the	the	DET
ajrhss-1518	21	7	overall	overall	ADJ
ajrhss-1518	21	8	structure	structure	NOUN
ajrhss-1518	21	9	of	of	ADP
ajrhss-1518	21	10	infectious	infectious	ADJ
ajrhss-1518	21	11	diseases	disease	NOUN
ajrhss-1518	21	12	is	be	AUX
ajrhss-1518	21	13	86.5–95	86.5–95	NUM
ajrhss-1518	21	14	%	%	NOUN
ajrhss-1518	21	15	,	,	PUNCT
ajrhss-1518	21	16	depending	depend	VERB
ajrhss-1518	21	17	on	on	ADP
ajrhss-1518	21	18	the	the	DET
ajrhss-1518	21	19	season	season	NOUN
ajrhss-1518	21	20	and	and	CCONJ
ajrhss-1518	21	21	age	age	NOUN
ajrhss-1518	21	22	.	.	PUNCT
ajrhss-1518	22	1	viral	viral	ADJ
ajrhss-1518	22	2	infections	infection	NOUN
ajrhss-1518	22	3	in	in	ADP
ajrhss-1518	22	4	children	child	NOUN
ajrhss-1518	22	5	account	account	VERB
ajrhss-1518	22	6	for	for	ADP
ajrhss-1518	22	7	more	more	ADJ
ajrhss-1518	22	8	than	than	ADP
ajrhss-1518	22	9	95	95	NUM
ajrhss-1518	22	10	%	%	NOUN
ajrhss-1518	22	11	,	,	PUNCT
ajrhss-1518	22	12	bacterial	bacterial	ADJ
ajrhss-1518	22	13	infections	infection	NOUN
ajrhss-1518	22	14	up	up	ADP
ajrhss-1518	22	15	to	to	PART
ajrhss-1518	22	16	3	3	NUM
ajrhss-1518	22	17	%	%	NOUN
ajrhss-1518	22	18	,	,	PUNCT
ajrhss-1518	22	19	and	and	CCONJ
ajrhss-1518	22	20	the	the	DET
ajrhss-1518	22	21	rest	rest	NOUN
ajrhss-1518	22	22	account	account	NOUN
ajrhss-1518	22	23	for	for	ADP
ajrhss-1518	22	24	less	less	ADJ
ajrhss-1518	22	25	than	than	ADP
ajrhss-1518	22	26	1	1	NUM
ajrhss-1518	22	27	%	%	NOUN
ajrhss-1518	22	28	of	of	ADP
ajrhss-1518	22	29	cases	case	NOUN
ajrhss-1518	22	30	.	.	PUNCT
ajrhss-1518	23	1	the	the	DET
ajrhss-1518	23	2	epidemic	epidemic	NOUN
ajrhss-1518	23	3	situation	situation	NOUN
ajrhss-1518	23	4	regarding	regard	VERB
ajrhss-1518	23	5	the	the	DET
ajrhss-1518	23	6	incidence	incidence	NOUN
ajrhss-1518	23	7	of	of	ADP
ajrhss-1518	23	8	arvi	arvi	NOUN
ajrhss-1518	23	9	,	,	PUNCT
ajrhss-1518	23	10	including	include	VERB
ajrhss-1518	23	11	influenza	influenza	NOUN
ajrhss-1518	23	12	,	,	PUNCT
ajrhss-1518	23	13	is	be	AUX
ajrhss-1518	23	14	determined	determine	VERB
ajrhss-1518	23	15	by	by	ADP
ajrhss-1518	23	16	children	child	NOUN
ajrhss-1518	23	17	more	more	ADJ
ajrhss-1518	23	18	than	than	ADP
ajrhss-1518	23	19	63.2	63.2	NUM
ajrhss-1518	23	20	%	%	NOUN
ajrhss-1518	23	21	.	.	PUNCT
ajrhss-1518	24	1	according	accord	VERB
ajrhss-1518	24	2	to	to	ADP
ajrhss-1518	24	3	the	the	DET
ajrhss-1518	24	4	world	world	PROPN
ajrhss-1518	24	5	health	health	PROPN
ajrhss-1518	24	6	organization	organization	NOUN
ajrhss-1518	24	7	,	,	PUNCT
ajrhss-1518	24	8	every	every	DET
ajrhss-1518	24	9	3–5th	3–5th	NUM
ajrhss-1518	24	10	child	child	NOUN
ajrhss-1518	24	11	and	and	CCONJ
ajrhss-1518	24	12	5–10th	5–10th	NUM
ajrhss-1518	24	13	adult	adult	NOUN
ajrhss-1518	24	14	suffer	suffer	VERB
ajrhss-1518	24	15	from	from	ADP
ajrhss-1518	24	16	influenza	influenza	NOUN
ajrhss-1518	24	17	every	every	DET
ajrhss-1518	24	18	year	year	NOUN
ajrhss-1518	24	19	worldwide	worldwide	ADV
ajrhss-1518	25	1	[	[	X
ajrhss-1518	25	2	2	2	NUM
ajrhss-1518	25	3	,	,	PUNCT
ajrhss-1518	25	4	3	3	NUM
ajrhss-1518	25	5	]	]	PUNCT
ajrhss-1518	25	6	.	.	PUNCT
ajrhss-1518	26	1	arvis	arvis	PROPN
ajrhss-1518	26	2	are	be	AUX
ajrhss-1518	26	3	among	among	ADP
ajrhss-1518	26	4	the	the	DET
ajrhss-1518	26	5	5	5	NUM
ajrhss-1518	26	6	leading	lead	VERB
ajrhss-1518	26	7	causes	cause	NOUN
ajrhss-1518	26	8	of	of	ADP
ajrhss-1518	26	9	death	death	NOUN
ajrhss-1518	26	10	in	in	ADP
ajrhss-1518	26	11	the	the	DET
ajrhss-1518	26	12	world	world	NOUN
ajrhss-1518	26	13	and	and	CCONJ
ajrhss-1518	26	14	pose	pose	VERB
ajrhss-1518	26	15	a	a	DET
ajrhss-1518	26	16	serious	serious	ADJ
ajrhss-1518	26	17	problem	problem	NOUN
ajrhss-1518	26	18	for	for	ADP
ajrhss-1518	26	19	the	the	DET
ajrhss-1518	26	20	public	public	ADJ
ajrhss-1518	26	21	health	health	NOUN
ajrhss-1518	26	22	of	of	ADP
ajrhss-1518	26	23	countries	country	NOUN
ajrhss-1518	26	24	,	,	PUNCT
ajrhss-1518	26	25	regardless	regardless	ADV
ajrhss-1518	26	26	of	of	ADP
ajrhss-1518	26	27	the	the	DET
ajrhss-1518	26	28	level	level	NOUN
ajrhss-1518	26	29	of	of	ADP
ajrhss-1518	26	30	economic	economic	ADJ
ajrhss-1518	26	31	development	development	NOUN
ajrhss-1518	26	32	,	,	PUNCT
ajrhss-1518	26	33	but	but	CCONJ
ajrhss-1518	26	34	are	be	AUX
ajrhss-1518	26	35	most	most	ADV
ajrhss-1518	26	36	relevant	relevant	ADJ
ajrhss-1518	26	37	for	for	ADP
ajrhss-1518	26	38	developing	develop	VERB
ajrhss-1518	26	39	countries	country	NOUN
ajrhss-1518	26	40	[	[	X
ajrhss-1518	26	41	4	4	NUM
ajrhss-1518	26	42	]	]	PUNCT
ajrhss-1518	26	43	.	.	PUNCT
ajrhss-1518	27	1	currently	currently	ADV
ajrhss-1518	27	2	,	,	PUNCT
ajrhss-1518	27	3	the	the	DET
ajrhss-1518	27	4	medical	medical	ADJ
ajrhss-1518	27	5	community	community	NOUN
ajrhss-1518	27	6	's	's	PART
ajrhss-1518	27	7	attention	attention	NOUN
ajrhss-1518	27	8	is	be	AUX
ajrhss-1518	27	9	focused	focus	VERB
ajrhss-1518	27	10	on	on	ADP
ajrhss-1518	27	11	the	the	DET
ajrhss-1518	27	12	incidence	incidence	NOUN
ajrhss-1518	27	13	of	of	ADP
ajrhss-1518	27	14	acute	acute	ADJ
ajrhss-1518	27	15	respiratory	respiratory	ADJ
ajrhss-1518	27	16	viral	viral	ADJ
ajrhss-1518	27	17	infections	infection	NOUN
ajrhss-1518	27	18	in	in	ADP
ajrhss-1518	27	19	children	child	NOUN
ajrhss-1518	27	20	and	and	CCONJ
ajrhss-1518	27	21	influenza	influenza	NOUN
ajrhss-1518	27	22	in	in	ADP
ajrhss-1518	27	23	adults	adult	NOUN
ajrhss-1518	27	24	,	,	PUNCT
ajrhss-1518	27	25	as	as	SCONJ
ajrhss-1518	27	26	there	there	PRON
ajrhss-1518	27	27	is	be	VERB
ajrhss-1518	27	28	an	an	DET
ajrhss-1518	27	29	underestimated	underestimated	ADJ
ajrhss-1518	27	30	burden	burden	NOUN
ajrhss-1518	27	31	of	of	ADP
ajrhss-1518	27	32	coinfection	coinfection	NOUN
ajrhss-1518	27	33	with	with	ADP
ajrhss-1518	27	34	2	2	NUM
ajrhss-1518	27	35	or	or	CCONJ
ajrhss-1518	27	36	more	more	ADJ
ajrhss-1518	27	37	viruses	virus	NOUN
ajrhss-1518	27	38	,	,	PUNCT
ajrhss-1518	27	39	which	which	PRON
ajrhss-1518	27	40	is	be	AUX
ajrhss-1518	27	41	exacerbated	exacerbate	VERB
ajrhss-1518	27	42	by	by	ADP
ajrhss-1518	27	43	the	the	DET
ajrhss-1518	27	44	ongoing	ongoing	ADJ
ajrhss-1518	27	45	covid-19	covid-19	PROPN
ajrhss-1518	27	46	pandemic	pandemic	NOUN
ajrhss-1518	27	47	.	.	PUNCT
ajrhss-1518	28	1	in	in	ADP
ajrhss-1518	28	2	addition	addition	NOUN
ajrhss-1518	28	3	,	,	PUNCT
ajrhss-1518	28	4	there	there	PRON
ajrhss-1518	28	5	are	be	VERB
ajrhss-1518	28	6	various	various	ADJ
ajrhss-1518	28	7	reasons	reason	NOUN
ajrhss-1518	28	8	why	why	SCONJ
ajrhss-1518	28	9	many	many	ADJ
ajrhss-1518	28	10	respiratory	respiratory	ADJ
ajrhss-1518	28	11	viruses	virus	NOUN
ajrhss-1518	28	12	are	be	AUX
ajrhss-1518	28	13	not	not	PART
ajrhss-1518	28	14	routinely	routinely	ADV
ajrhss-1518	28	15	detected	detect	VERB
ajrhss-1518	28	16	and	and	CCONJ
ajrhss-1518	28	17	can	can	AUX
ajrhss-1518	28	18	therefore	therefore	ADV
ajrhss-1518	28	19	be	be	AUX
ajrhss-1518	28	20	considered	consider	VERB
ajrhss-1518	28	21	diagnostically	diagnostically	ADV
ajrhss-1518	28	22	and	and	CCONJ
ajrhss-1518	28	23	clinically	clinically	ADV
ajrhss-1518	28	24	ignorable	ignorable	ADJ
ajrhss-1518	28	25	[	[	X
ajrhss-1518	28	26	5–7	5–7	NOUN
ajrhss-1518	28	27	]	]	PUNCT
ajrhss-1518	28	28	.	.	PUNCT
ajrhss-1518	29	1	the	the	DET
ajrhss-1518	29	2	procedure	procedure	NOUN
ajrhss-1518	29	3	for	for	ADP
ajrhss-1518	29	4	providing	provide	VERB
ajrhss-1518	29	5	care	care	NOUN
ajrhss-1518	29	6	implies	imply	VERB
ajrhss-1518	29	7	that	that	SCONJ
ajrhss-1518	29	8	a	a	DET
ajrhss-1518	29	9	child	child	NOUN
ajrhss-1518	29	10	with	with	ADP
ajrhss-1518	29	11	arvi	arvi	NOUN
ajrhss-1518	29	12	is	be	AUX
ajrhss-1518	29	13	usually	usually	ADV
ajrhss-1518	29	14	observed	observe	VERB
ajrhss-1518	29	15	in	in	ADP
ajrhss-1518	29	16	an	an	DET
ajrhss-1518	29	17	outpatient	outpatient	NOUN
ajrhss-1518	29	18	setting	setting	NOUN
ajrhss-1518	29	19	by	by	ADP
ajrhss-1518	29	20	a	a	DET
ajrhss-1518	29	21	pediatrician	pediatrician	NOUN
ajrhss-1518	29	22	.	.	PUNCT
ajrhss-1518	30	1	inpatient	inpatient	NOUN
ajrhss-1518	30	2	treatment	treatment	NOUN
ajrhss-1518	30	3	(	(	PUNCT
ajrhss-1518	30	4	hospitalization	hospitalization	NOUN
ajrhss-1518	30	5	)	)	PUNCT
ajrhss-1518	30	6	may	may	AUX
ajrhss-1518	30	7	be	be	AUX
ajrhss-1518	30	8	required	require	VERB
ajrhss-1518	30	9	if	if	SCONJ
ajrhss-1518	30	10	complications	complication	NOUN
ajrhss-1518	30	11	develop	develop	VERB
ajrhss-1518	30	12	and	and	CCONJ
ajrhss-1518	30	13	febrile	febrile	NOUN
ajrhss-1518	30	14	fever	fever	NOUN
ajrhss-1518	30	15	develops	develop	VERB
ajrhss-1518	30	16	for	for	ADP
ajrhss-1518	30	17	a	a	DET
ajrhss-1518	30	18	long	long	ADJ
ajrhss-1518	30	19	time	time	NOUN
ajrhss-1518	30	20	.	.	PUNCT
ajrhss-1518	31	1	complications	complication	NOUN
ajrhss-1518	31	2	of	of	ADP
ajrhss-1518	31	3	arvi	arvi	NOUN
ajrhss-1518	31	4	in	in	ADP
ajrhss-1518	31	5	most	most	ADJ
ajrhss-1518	31	6	cases	case	NOUN
ajrhss-1518	31	7	are	be	AUX
ajrhss-1518	31	8	determined	determine	VERB
ajrhss-1518	31	9	by	by	ADP
ajrhss-1518	31	10	the	the	DET
ajrhss-1518	31	11	addition	addition	NOUN
ajrhss-1518	31	12	of	of	ADP
ajrhss-1518	31	13	a	a	DET
ajrhss-1518	31	14	bacterial	bacterial	ADJ
ajrhss-1518	31	15	infection	infection	NOUN
ajrhss-1518	31	16	.	.	PUNCT
ajrhss-1518	32	1	thus	thus	ADV
ajrhss-1518	32	2	,	,	PUNCT
ajrhss-1518	32	3	there	there	PRON
ajrhss-1518	32	4	is	be	VERB
ajrhss-1518	32	5	a	a	DET
ajrhss-1518	32	6	risk	risk	NOUN
ajrhss-1518	32	7	of	of	ADP
ajrhss-1518	32	8	developing	develop	VERB
ajrhss-1518	32	9	acute	acute	ADJ
ajrhss-1518	32	10	otitis	otitis	NOUN
ajrhss-1518	32	11	media	medium	NOUN
ajrhss-1518	32	12	against	against	ADP
ajrhss-1518	32	13	the	the	DET
ajrhss-1518	32	14	background	background	NOUN
ajrhss-1518	32	15	of	of	ADP
ajrhss-1518	32	16	nasopharyngitis	nasopharyngitis	NOUN
ajrhss-1518	32	17	,	,	PUNCT
ajrhss-1518	32	18	especially	especially	ADV
ajrhss-1518	32	19	in	in	ADP
ajrhss-1518	32	20	young	young	ADJ
ajrhss-1518	32	21	children	child	NOUN
ajrhss-1518	32	22	,	,	PUNCT
ajrhss-1518	32	23	usually	usually	ADV
ajrhss-1518	32	24	on	on	ADP
ajrhss-1518	32	25	the	the	DET
ajrhss-1518	32	26	2nd–5th	2nd–5th	NUM
ajrhss-1518	32	27	day	day	NOUN
ajrhss-1518	32	28	of	of	ADP
ajrhss-1518	32	29	illness	illness	NOUN
ajrhss-1518	32	30	.	.	PUNCT
ajrhss-1518	33	1	its	its	PRON
ajrhss-1518	33	2	frequency	frequency	NOUN
ajrhss-1518	33	3	can	can	AUX
ajrhss-1518	33	4	reach	reach	VERB
ajrhss-1518	33	5	20–40	20–40	NUM
ajrhss-1518	33	6	%	%	NOUN
ajrhss-1518	33	7	[	[	X
ajrhss-1518	33	8	8	8	NUM
ajrhss-1518	33	9	,	,	PUNCT
ajrhss-1518	33	10	9	9	NUM
ajrhss-1518	33	11	]	]	PUNCT
ajrhss-1518	33	12	.	.	PUNCT
ajrhss-1518	34	1	in	in	ADP
ajrhss-1518	34	2	addition	addition	NOUN
ajrhss-1518	34	3	,	,	PUNCT
ajrhss-1518	34	4	a	a	DET
ajrhss-1518	34	5	respiratory	respiratory	ADJ
ajrhss-1518	34	6	infection	infection	NOUN
ajrhss-1518	34	7	can	can	AUX
ajrhss-1518	34	8	be	be	AUX
ajrhss-1518	34	9	a	a	DET
ajrhss-1518	34	10	trigger	trigger	NOUN
ajrhss-1518	34	11	for	for	ADP
ajrhss-1518	34	12	exacerbation	exacerbation	NOUN
ajrhss-1518	34	13	of	of	ADP
ajrhss-1518	34	14	chronic	chronic	ADJ
ajrhss-1518	34	15	diseases	disease	NOUN
ajrhss-1518	34	16	,	,	PUNCT
ajrhss-1518	34	17	most	most	ADV
ajrhss-1518	34	18	often	often	ADV
ajrhss-1518	34	19	bronchial	bronchial	ADJ
ajrhss-1518	34	20	asthma	asthma	NOUN
ajrhss-1518	34	21	and	and	CCONJ
ajrhss-1518	34	22	urinary	urinary	ADJ
ajrhss-1518	34	23	tract	tract	NOUN
ajrhss-1518	34	24	infections	infection	NOUN
ajrhss-1518	34	25	[	[	X
ajrhss-1518	34	26	1	1	NUM
ajrhss-1518	34	27	]	]	PUNCT
ajrhss-1518	34	28	.	.	PUNCT
ajrhss-1518	35	1	the	the	DET
ajrhss-1518	35	2	incidence	incidence	NOUN
ajrhss-1518	35	3	of	of	ADP
ajrhss-1518	35	4	arvi	arvi	NOUN
ajrhss-1518	35	5	is	be	AUX
ajrhss-1518	35	6	highest	high	ADJ
ajrhss-1518	35	7	between	between	ADP
ajrhss-1518	35	8	september	september	PROPN
ajrhss-1518	35	9	and	and	CCONJ
ajrhss-1518	35	10	april	april	PROPN
ajrhss-1518	35	11	,	,	PUNCT
ajrhss-1518	35	12	with	with	ADP
ajrhss-1518	35	13	the	the	DET
ajrhss-1518	35	14	peak	peak	NOUN
ajrhss-1518	35	15	incidence	incidence	NOUN
ajrhss-1518	35	16	occurring	occur	VERB
ajrhss-1518	35	17	in	in	ADP
ajrhss-1518	35	18	february	february	PROPN
ajrhss-1518	35	19	and	and	CCONJ
ajrhss-1518	35	20	march	march	PROPN
ajrhss-1518	35	21	.	.	PUNCT
ajrhss-1518	36	1	as	as	ADP
ajrhss-1518	36	2	of	of	ADP
ajrhss-1518	36	3	41	41	NUM
ajrhss-1518	36	4	weeks	week	NOUN
ajrhss-1518	36	5	2022	2022	NUM
ajrhss-1518	36	6	(	(	PUNCT
ajrhss-1518	36	7	10/17/2022–10/23/2022	10/17/2022–10/23/2022	NUM
ajrhss-1518	36	8	)	)	PUNCT
ajrhss-1518	36	9	in	in	ADP
ajrhss-1518	36	10	the	the	DET
ajrhss-1518	36	11	territory	territory	NOUN
ajrhss-1518	36	12	of	of	ADP
ajrhss-1518	36	13	bukhara	bukhara	PROPN
ajrhss-1518	36	14	.	.	PUNCT
ajrhss-1518	37	1	during	during	ADP
ajrhss-1518	37	2	the	the	DET
ajrhss-1518	37	3	inter	inter	ADJ
ajrhss-1518	37	4	-	-	ADJ
ajrhss-1518	37	5	epidemic	epidemic	ADJ
ajrhss-1518	37	6	period	period	NOUN
ajrhss-1518	37	7	for	for	ADP
ajrhss-1518	37	8	influenza	influenza	NOUN
ajrhss-1518	37	9	,	,	PUNCT
ajrhss-1518	37	10	the	the	DET
ajrhss-1518	37	11	incidence	incidence	NOUN
ajrhss-1518	37	12	of	of	ADP
ajrhss-1518	37	13	arvi	arvi	NOUN
ajrhss-1518	37	14	is	be	AUX
ajrhss-1518	37	15	caused	cause	VERB
ajrhss-1518	37	16	by	by	ADP
ajrhss-1518	37	17	respiratory	respiratory	ADJ
ajrhss-1518	37	18	viruses	virus	NOUN
ajrhss-1518	37	19	of	of	ADP
ajrhss-1518	37	20	noninfluenza	noninfluenza	ADV
ajrhss-1518	37	21	etiology	etiology	NOUN
ajrhss-1518	37	22	(	(	PUNCT
ajrhss-1518	37	23	rhinoviruses	rhinovirus	NOUN
ajrhss-1518	37	24	,	,	PUNCT
ajrhss-1518	37	25	parainfluenza	parainfluenza	ADJ
ajrhss-1518	37	26	viruses	virus	NOUN
ajrhss-1518	37	27	,	,	PUNCT
ajrhss-1518	37	28	adenoviruses	adenovirus	NOUN
ajrhss-1518	37	29	,	,	PUNCT
ajrhss-1518	37	30	respiratory	respiratory	ADJ
ajrhss-1518	37	31	syncytial	syncytial	ADJ
ajrhss-1518	37	32	viruses	virus	NOUN
ajrhss-1518	37	33	,	,	PUNCT
ajrhss-1518	37	34	etc	etc	X
ajrhss-1518	37	35	.	.	X
ajrhss-1518	37	36	)	)	PUNCT
ajrhss-1518	38	1	[	[	X
ajrhss-1518	38	2	10	10	NUM
ajrhss-1518	38	3	]	]	PUNCT
ajrhss-1518	38	4	.	.	PUNCT
ajrhss-1518	39	1	the	the	DET
ajrhss-1518	39	2	current	current	ADJ
ajrhss-1518	39	3	clinical	clinical	ADJ
ajrhss-1518	39	4	recommendations	recommendation	NOUN
ajrhss-1518	39	5	of	of	ADP
ajrhss-1518	39	6	the	the	DET
ajrhss-1518	39	7	ministry	ministry	PROPN
ajrhss-1518	39	8	of	of	ADP
ajrhss-1518	39	9	health	health	PROPN
ajrhss-1518	39	10	for	for	ADP
ajrhss-1518	39	11	the	the	DET
ajrhss-1518	39	12	treatment	treatment	NOUN
ajrhss-1518	39	13	of	of	ADP
ajrhss-1518	39	14	influenza	influenza	NOUN
ajrhss-1518	39	15	and	and	CCONJ
ajrhss-1518	39	16	arvi	arvi	NOUN
ajrhss-1518	39	17	in	in	ADP
ajrhss-1518	39	18	adults	adult	NOUN
ajrhss-1518	39	19	emphasize	emphasize	VERB
ajrhss-1518	39	20	the	the	DET
ajrhss-1518	39	21	importance	importance	NOUN
ajrhss-1518	39	22	of	of	ADP
ajrhss-1518	39	23	early	early	ADJ
ajrhss-1518	39	24	prescription	prescription	NOUN
ajrhss-1518	39	25	of	of	ADP
ajrhss-1518	39	26	etiotropic	etiotropic	NOUN
ajrhss-1518	39	27	therapy	therapy	NOUN
ajrhss-1518	39	28	for	for	ADP
ajrhss-1518	39	29	viral	viral	ADJ
ajrhss-1518	39	30	infections	infection	NOUN
ajrhss-1518	39	31	and	and	CCONJ
ajrhss-1518	39	32	the	the	DET
ajrhss-1518	39	33	need	need	NOUN
ajrhss-1518	39	34	to	to	PART
ajrhss-1518	39	35	make	make	VERB
ajrhss-1518	39	36	efforts	effort	NOUN
ajrhss-1518	39	37	to	to	PART
ajrhss-1518	39	38	find	find	VERB
ajrhss-1518	39	39	new	new	ADJ
ajrhss-1518	39	40	etiotropic	etiotropic	NOUN
ajrhss-1518	39	41	antiviral	antiviral	ADJ
ajrhss-1518	39	42	drugs	drug	NOUN
ajrhss-1518	39	43	aimed	aim	VERB
ajrhss-1518	39	44	directly	directly	ADV
ajrhss-1518	39	45	at	at	ADP
ajrhss-1518	39	46	the	the	DET
ajrhss-1518	39	47	life	life	NOUN
ajrhss-1518	39	48	cycle	cycle	NOUN
ajrhss-1518	39	49	of	of	ADP
ajrhss-1518	39	50	viruses	virus	NOUN
ajrhss-1518	39	51	,	,	PUNCT
ajrhss-1518	39	52	namely	namely	ADV
ajrhss-1518	39	53	,	,	PUNCT
ajrhss-1518	39	54	inhibiting	inhibit	VERB
ajrhss-1518	39	55	the	the	DET
ajrhss-1518	39	56	process	process	NOUN
ajrhss-1518	39	57	of	of	ADP
ajrhss-1518	39	58	viral	viral	ADJ
ajrhss-1518	39	59	replication	replication	NOUN
ajrhss-1518	39	60	.	.	PUNCT
ajrhss-1518	40	1	one	one	NUM
ajrhss-1518	40	2	of	of	ADP
ajrhss-1518	40	3	the	the	DET
ajrhss-1518	40	4	etiotropic	etiotropic	NOUN
ajrhss-1518	40	5	antiviral	antiviral	ADJ
ajrhss-1518	40	6	drugs	drug	NOUN
ajrhss-1518	40	7	recommended	recommend	VERB
ajrhss-1518	40	8	by	by	ADP
ajrhss-1518	40	9	the	the	DET
ajrhss-1518	40	10	ministry	ministry	PROPN
ajrhss-1518	40	11	of	of	ADP
ajrhss-1518	40	12	health	health	PROPN
ajrhss-1518	40	13	for	for	ADP
ajrhss-1518	40	14	the	the	DET
ajrhss-1518	40	15	treatment	treatment	NOUN
ajrhss-1518	40	16	of	of	ADP
ajrhss-1518	40	17	influenza	influenza	NOUN
ajrhss-1518	40	18	and	and	CCONJ
ajrhss-1518	40	19	arvi	arvi	NOUN
ajrhss-1518	40	20	in	in	ADP
ajrhss-1518	40	21	adults	adult	NOUN
ajrhss-1518	40	22	is	be	AUX
ajrhss-1518	40	23	the	the	DET
ajrhss-1518	40	24	drug	drug	NOUN
ajrhss-1518	40	25	riamilovir	riamilovir	X
ajrhss-1518	41	1	[	[	X
ajrhss-1518	41	2	11	11	NUM
ajrhss-1518	41	3	,	,	PUNCT
ajrhss-1518	41	4	12	12	NUM
ajrhss-1518	41	5	]	]	PUNCT
ajrhss-1518	41	6	.	.	PUNCT
ajrhss-1518	42	1	the	the	DET
ajrhss-1518	42	2	basis	basis	NOUN
ajrhss-1518	42	3	for	for	ADP
ajrhss-1518	42	4	including	include	VERB
ajrhss-1518	42	5	the	the	DET
ajrhss-1518	42	6	drug	drug	NOUN
ajrhss-1518	42	7	riamilovir	riamilovir	PRON
ajrhss-1518	42	8	in	in	ADP
ajrhss-1518	42	9	the	the	DET
ajrhss-1518	42	10	clinical	clinical	ADJ
ajrhss-1518	42	11	recommendations	recommendation	NOUN
ajrhss-1518	42	12	of	of	ADP
ajrhss-1518	42	13	the	the	DET
ajrhss-1518	42	14	ministry	ministry	PROPN
ajrhss-1518	42	15	of	of	ADP
ajrhss-1518	42	16	health	health	PROPN
ajrhss-1518	42	17	were	be	AUX
ajrhss-1518	42	18	the	the	DET
ajrhss-1518	42	19	results	result	NOUN
ajrhss-1518	42	20	of	of	ADP
ajrhss-1518	42	21	multicenter	multicenter	NOUN
ajrhss-1518	42	22	randomized	randomize	VERB
ajrhss-1518	42	23	comparative	comparative	ADJ
ajrhss-1518	42	24	clinical	clinical	ADJ
ajrhss-1518	42	25	studies	study	NOUN
ajrhss-1518	42	26	in	in	ADP
ajrhss-1518	42	27	patients	patient	NOUN
ajrhss-1518	42	28	over	over	ADP
ajrhss-1518	42	29	18	18	NUM
ajrhss-1518	42	30	years	year	NOUN
ajrhss-1518	42	31	of	of	ADP
ajrhss-1518	42	32	age	age	NOUN
ajrhss-1518	42	33	with	with	ADP
ajrhss-1518	42	34	diagnoses	diagnosis	NOUN
ajrhss-1518	42	35	of	of	ADP
ajrhss-1518	42	36	arvi	arvi	NOUN
ajrhss-1518	42	37	and	and	CCONJ
ajrhss-1518	42	38	influenza	influenza	NOUN
ajrhss-1518	42	39	,	,	PUNCT
ajrhss-1518	42	40	which	which	PRON
ajrhss-1518	42	41	established	establish	VERB
ajrhss-1518	42	42	the	the	DET
ajrhss-1518	42	43	high	high	ADJ
ajrhss-1518	42	44	antiviral	antiviral	ADJ
ajrhss-1518	42	45	efficacy	efficacy	NOUN
ajrhss-1518	42	46	,	,	PUNCT
ajrhss-1518	42	47	safety	safety	NOUN
ajrhss-1518	42	48	and	and	CCONJ
ajrhss-1518	42	49	good	good	ADJ
ajrhss-1518	42	50	tolerability	tolerability	NOUN
ajrhss-1518	42	51	of	of	ADP
ajrhss-1518	42	52	the	the	DET
ajrhss-1518	42	53	drug	drug	NOUN
ajrhss-1518	42	54	riamilovir	riamilovir	PRON
ajrhss-1518	42	55	in	in	ADP
ajrhss-1518	42	56	the	the	DET
ajrhss-1518	42	57	treatment	treatment	NOUN
ajrhss-1518	42	58	of	of	ADP
ajrhss-1518	42	59	viral	viral	ADJ
ajrhss-1518	42	60	infections	infection	NOUN
ajrhss-1518	42	61	[	[	X
ajrhss-1518	42	62	13–17	13–17	NUM
ajrhss-1518	42	63	]	]	PUNCT
ajrhss-1518	42	64	.	.	PUNCT
ajrhss-1518	43	1	in	in	ADP
ajrhss-1518	43	2	addition	addition	NOUN
ajrhss-1518	43	3	,	,	PUNCT
ajrhss-1518	43	4	therapy	therapy	NOUN
ajrhss-1518	43	5	with	with	ADP
ajrhss-1518	43	6	the	the	DET
ajrhss-1518	43	7	drug	drug	NOUN
ajrhss-1518	43	8	riamilovir	riamilovir	PRON
ajrhss-1518	43	9	has	have	VERB
ajrhss-1518	43	10	statistically	statistically	ADV
ajrhss-1518	43	11	significant	significant	ADJ
ajrhss-1518	43	12	advantages	advantage	NOUN
ajrhss-1518	43	13	in	in	ADP
ajrhss-1518	43	14	various	various	ADJ
ajrhss-1518	43	15	indicators	indicator	NOUN
ajrhss-1518	43	16	compared	compare	VERB
ajrhss-1518	43	17	to	to	ADP
ajrhss-1518	43	18	both	both	DET
ajrhss-1518	43	19	the	the	DET
ajrhss-1518	43	20	placebo	placebo	NOUN
ajrhss-1518	43	21	group	group	NOUN
ajrhss-1518	43	22	and	and	CCONJ
ajrhss-1518	43	23	the	the	DET
ajrhss-1518	43	24	comparison	comparison	NOUN
ajrhss-1518	43	25	group	group	NOUN
ajrhss-1518	43	26	(	(	PUNCT
ajrhss-1518	43	27	oseltamivir	oseltamivir	PROPN
ajrhss-1518	43	28	)	)	PUNCT
ajrhss-1518	44	1	[	[	X
ajrhss-1518	44	2	18	18	NUM
ajrhss-1518	44	3	,	,	PUNCT
ajrhss-1518	44	4	19	19	NUM
ajrhss-1518	44	5	]	]	PUNCT
ajrhss-1518	44	6	.	.	PUNCT
ajrhss-1518	45	1	the	the	DET
ajrhss-1518	45	2	results	result	NOUN
ajrhss-1518	45	3	obtained	obtain	VERB
ajrhss-1518	45	4	in	in	ADP
ajrhss-1518	45	5	adult	adult	NOUN
ajrhss-1518	45	6	patients	patient	NOUN
ajrhss-1518	45	7	made	make	VERB
ajrhss-1518	45	8	it	it	PRON
ajrhss-1518	45	9	possible	possible	ADJ
ajrhss-1518	45	10	to	to	PART
ajrhss-1518	45	11	plan	plan	VERB
ajrhss-1518	45	12	and	and	CCONJ
ajrhss-1518	45	13	conduct	conduct	VERB
ajrhss-1518	45	14	a	a	DET
ajrhss-1518	45	15	multicenter	multicenter	NOUN
ajrhss-1518	45	16	,	,	PUNCT
ajrhss-1518	45	17	randomized	randomize	VERB
ajrhss-1518	45	18	,	,	PUNCT
ajrhss-1518	45	19	double	double	ADJ
ajrhss-1518	45	20	-	-	PUNCT
ajrhss-1518	45	21	blind	blind	ADJ
ajrhss-1518	45	22	,	,	PUNCT
ajrhss-1518	45	23	comparative	comparative	ADJ
ajrhss-1518	45	24	,	,	PUNCT
ajrhss-1518	45	25	placebo	placebo	NOUN
ajrhss-1518	45	26	-	-	PUNCT
ajrhss-1518	45	27	controlled	control	VERB
ajrhss-1518	45	28	study	study	NOUN
ajrhss-1518	45	29	of	of	ADP
ajrhss-1518	45	30	the	the	DET
ajrhss-1518	45	31	effectiveness	effectiveness	NOUN
ajrhss-1518	45	32	and	and	CCONJ
ajrhss-1518	45	33	safety	safety	NOUN
ajrhss-1518	45	34	of	of	ADP
ajrhss-1518	45	35	the	the	DET
ajrhss-1518	45	36	drug	drug	NOUN
ajrhss-1518	45	37	riamilovir	riamilovir	PRON
ajrhss-1518	45	38	(	(	PUNCT
ajrhss-1518	45	39	100	100	NUM
ajrhss-1518	45	40	mg	mg	ADJ
ajrhss-1518	45	41	capsules	capsule	NOUN
ajrhss-1518	45	42	)	)	PUNCT
ajrhss-1518	45	43	in	in	ADP
ajrhss-1518	45	44	children	child	NOUN
ajrhss-1518	45	45	aged	age	VERB
ajrhss-1518	45	46	12–17	12–17	NUM
ajrhss-1518	45	47	years	year	NOUN
ajrhss-1518	45	48	diagnosed	diagnose	VERB
ajrhss-1518	45	49	with	with	ADP
ajrhss-1518	45	50	arvi	arvi	NOUN
ajrhss-1518	45	51	.	.	PUNCT
ajrhss-1518	46	1	american	american	PROPN
ajrhss-1518	46	2	journal	journal	PROPN
ajrhss-1518	46	3	of	of	ADP
ajrhss-1518	46	4	research	research	NOUN
ajrhss-1518	46	5	in	in	ADP
ajrhss-1518	46	6	humanities	humanity	NOUN
ajrhss-1518	46	7	and	and	CCONJ
ajrhss-1518	46	8	social	social	ADJ
ajrhss-1518	46	9	sciences	science	NOUN
ajrhss-1518	46	10	volume	volume	NOUN
ajrhss-1518	46	11	18	18	NUM
ajrhss-1518	46	12	nov	nov	PROPN
ajrhss-1518	46	13	.	.	PROPN
ajrhss-1518	46	14	,	,	PUNCT
ajrhss-1518	46	15	2023	2023	NUM
ajrhss-1518	46	16	p	p	NOUN
ajrhss-1518	46	17	a	a	DET
ajrhss-1518	46	18	g	g	NOUN
ajrhss-1518	46	19	e	e	PROPN
ajrhss-1518	46	20	|	|	NOUN
ajrhss-1518	46	21	138	138	NUM
ajrhss-1518	46	22	www.americanjournal.org	www.americanjournal.org	NOUN
ajrhss-1518	46	23	the	the	DET
ajrhss-1518	46	24	purpose	purpose	NOUN
ajrhss-1518	46	25	of	of	ADP
ajrhss-1518	46	26	the	the	DET
ajrhss-1518	46	27	study	study	NOUN
ajrhss-1518	46	28	is	be	AUX
ajrhss-1518	46	29	to	to	PART
ajrhss-1518	46	30	confirm	confirm	VERB
ajrhss-1518	46	31	the	the	DET
ajrhss-1518	46	32	effectiveness	effectiveness	NOUN
ajrhss-1518	46	33	and	and	CCONJ
ajrhss-1518	46	34	safety	safety	NOUN
ajrhss-1518	46	35	of	of	ADP
ajrhss-1518	46	36	the	the	DET
ajrhss-1518	46	37	drug	drug	NOUN
ajrhss-1518	46	38	riamilovir	riamilovir	PRON
ajrhss-1518	46	39	capsules	capsule	VERB
ajrhss-1518	46	40	100	100	NUM
ajrhss-1518	46	41	mg	mg	NOUN
ajrhss-1518	46	42	in	in	ADP
ajrhss-1518	46	43	children	child	NOUN
ajrhss-1518	46	44	12–17	12–17	NUM
ajrhss-1518	46	45	years	year	NOUN
ajrhss-1518	46	46	old	old	ADJ
ajrhss-1518	46	47	diagnosed	diagnose	VERB
ajrhss-1518	46	48	with	with	ADP
ajrhss-1518	46	49	arvi	arvi	NOUN
ajrhss-1518	46	50	.	.	PUNCT
ajrhss-1518	47	1	to	to	PART
ajrhss-1518	47	2	achieve	achieve	VERB
ajrhss-1518	47	3	this	this	DET
ajrhss-1518	47	4	goal	goal	NOUN
ajrhss-1518	47	5	,	,	PUNCT
ajrhss-1518	47	6	it	it	PRON
ajrhss-1518	47	7	was	be	AUX
ajrhss-1518	47	8	planned	plan	VERB
ajrhss-1518	47	9	to	to	PART
ajrhss-1518	47	10	solve	solve	VERB
ajrhss-1518	47	11	the	the	DET
ajrhss-1518	47	12	following	following	ADJ
ajrhss-1518	47	13	tasks	task	NOUN
ajrhss-1518	47	14	:	:	PUNCT
ajrhss-1518	47	15	to	to	PART
ajrhss-1518	47	16	evaluate	evaluate	VERB
ajrhss-1518	47	17	the	the	DET
ajrhss-1518	47	18	effectiveness	effectiveness	NOUN
ajrhss-1518	47	19	and	and	CCONJ
ajrhss-1518	47	20	safety	safety	NOUN
ajrhss-1518	47	21	of	of	ADP
ajrhss-1518	47	22	the	the	DET
ajrhss-1518	47	23	drug	drug	NOUN
ajrhss-1518	47	24	riamilovir	riamilovir	PRON
ajrhss-1518	47	25	,	,	PUNCT
ajrhss-1518	47	26	100	100	NUM
ajrhss-1518	47	27	mg	mg	ADJ
ajrhss-1518	47	28	capsules	capsule	NOUN
ajrhss-1518	47	29	,	,	PUNCT
ajrhss-1518	47	30	in	in	ADP
ajrhss-1518	47	31	comparison	comparison	NOUN
ajrhss-1518	47	32	with	with	ADP
ajrhss-1518	47	33	placebo	placebo	NOUN
ajrhss-1518	47	34	as	as	ADP
ajrhss-1518	47	35	part	part	NOUN
ajrhss-1518	47	36	of	of	ADP
ajrhss-1518	47	37	the	the	DET
ajrhss-1518	47	38	treatment	treatment	NOUN
ajrhss-1518	47	39	of	of	ADP
ajrhss-1518	47	40	arvi	arvi	NOUN
ajrhss-1518	47	41	in	in	ADP
ajrhss-1518	47	42	children	child	NOUN
ajrhss-1518	47	43	aged	aged	ADJ
ajrhss-1518	47	44	12–17	12–17	NUM
ajrhss-1518	47	45	years	year	NOUN
ajrhss-1518	47	46	;	;	PUNCT
ajrhss-1518	47	47	-to	-to	CCONJ
ajrhss-1518	47	48	study	study	VERB
ajrhss-1518	47	49	the	the	DET
ajrhss-1518	47	50	pharmacokinetics	pharmacokinetic	NOUN
ajrhss-1518	47	51	of	of	ADP
ajrhss-1518	47	52	the	the	DET
ajrhss-1518	47	53	drug	drug	NOUN
ajrhss-1518	47	54	riamilovir	riamilovir	PRON
ajrhss-1518	47	55	,	,	PUNCT
ajrhss-1518	47	56	100	100	NUM
ajrhss-1518	47	57	mg	mg	ADJ
ajrhss-1518	47	58	capsules	capsule	NOUN
ajrhss-1518	47	59	,	,	PUNCT
ajrhss-1518	47	60	in	in	ADP
ajrhss-1518	47	61	children	child	NOUN
ajrhss-1518	47	62	aged	age	VERB
ajrhss-1518	47	63	12–17	12–17	NUM
ajrhss-1518	47	64	years	year	NOUN
ajrhss-1518	47	65	.	.	PUNCT
ajrhss-1518	48	1	materials	material	NOUN
ajrhss-1518	48	2	and	and	CCONJ
ajrhss-1518	48	3	methods	method	NOUN
ajrhss-1518	48	4	the	the	DET
ajrhss-1518	48	5	multicenter	multicenter	NOUN
ajrhss-1518	48	6	randomized	randomize	VERB
ajrhss-1518	48	7	placebo	placebo	NOUN
ajrhss-1518	48	8	-	-	PUNCT
ajrhss-1518	48	9	controlled	control	VERB
ajrhss-1518	48	10	study	study	NOUN
ajrhss-1518	48	11	included	include	VERB
ajrhss-1518	48	12	269	269	NUM
ajrhss-1518	48	13	patients	patient	NOUN
ajrhss-1518	48	14	with	with	ADP
ajrhss-1518	48	15	a	a	DET
ajrhss-1518	48	16	clinically	clinically	ADV
ajrhss-1518	48	17	and	and	CCONJ
ajrhss-1518	48	18	laboratory	laboratory	NOUN
ajrhss-1518	48	19	(	(	PUNCT
ajrhss-1518	48	20	polymerase	polymerase	NOUN
ajrhss-1518	48	21	chain	chain	NOUN
ajrhss-1518	48	22	reaction	reaction	NOUN
ajrhss-1518	48	23	pcr	pcr	PROPN
ajrhss-1518	48	24	)	)	PUNCT
ajrhss-1518	48	25	confirmed	confirm	VERB
ajrhss-1518	48	26	diagnosis	diagnosis	NOUN
ajrhss-1518	48	27	of	of	ADP
ajrhss-1518	48	28	arvi	arvi	NOUN
ajrhss-1518	48	29	(	(	PUNCT
ajrhss-1518	48	30	icd-10	icd-10	DET
ajrhss-1518	48	31	codes	code	NOUN
ajrhss-1518	48	32	:	:	PUNCT
ajrhss-1518	48	33	j00	j00	PROPN
ajrhss-1518	48	34	,	,	PUNCT
ajrhss-1518	48	35	j02	j02	PROPN
ajrhss-1518	48	36	,	,	PUNCT
ajrhss-1518	48	37	j02.9	j02.9	PROPN
ajrhss-1518	48	38	,	,	PUNCT
ajrhss-1518	48	39	j04	j04	NOUN
ajrhss-1518	48	40	,	,	PUNCT
ajrhss-1518	48	41	j04.0	j04.0	PROPN
ajrhss-1518	48	42	,	,	PUNCT
ajrhss-1518	48	43	j04.1	j04.1	NOUN
ajrhss-1518	48	44	,	,	PUNCT
ajrhss-1518	48	45	j04.2	j04.2	PROPN
ajrhss-1518	48	46	,	,	PUNCT
ajrhss-1518	48	47	j06	j06	PROPN
ajrhss-1518	48	48	,	,	PUNCT
ajrhss-1518	48	49	j06.0	j06.0	PROPN
ajrhss-1518	48	50	,	,	PUNCT
ajrhss-1518	48	51	j06.9	j06.9	PROPN
ajrhss-1518	48	52	)	)	PUNCT
ajrhss-1518	48	53	.	.	PUNCT
ajrhss-1518	49	1	inclusion	inclusion	NOUN
ajrhss-1518	49	2	in	in	ADP
ajrhss-1518	49	3	the	the	DET
ajrhss-1518	49	4	study	study	NOUN
ajrhss-1518	49	5	occurred	occur	VERB
ajrhss-1518	49	6	after	after	ADP
ajrhss-1518	49	7	one	one	NUM
ajrhss-1518	49	8	of	of	ADP
ajrhss-1518	49	9	the	the	DET
ajrhss-1518	49	10	parents	parent	NOUN
ajrhss-1518	49	11	/	/	SYM
ajrhss-1518	49	12	adoptive	adoptive	ADJ
ajrhss-1518	49	13	parents	parent	NOUN
ajrhss-1518	49	14	and	and	CCONJ
ajrhss-1518	49	15	the	the	DET
ajrhss-1518	49	16	patient	patient	NOUN
ajrhss-1518	49	17	himself	himself	PRON
ajrhss-1518	49	18	signed	sign	VERB
ajrhss-1518	49	19	an	an	DET
ajrhss-1518	49	20	informed	informed	ADJ
ajrhss-1518	49	21	consent	consent	NOUN
ajrhss-1518	49	22	to	to	PART
ajrhss-1518	49	23	participate	participate	VERB
ajrhss-1518	49	24	in	in	ADP
ajrhss-1518	49	25	the	the	DET
ajrhss-1518	49	26	study	study	NOUN
ajrhss-1518	49	27	.	.	PUNCT
ajrhss-1518	50	1	the	the	DET
ajrhss-1518	50	2	interval	interval	NOUN
ajrhss-1518	50	3	between	between	ADP
ajrhss-1518	50	4	the	the	DET
ajrhss-1518	50	5	appearance	appearance	NOUN
ajrhss-1518	50	6	of	of	ADP
ajrhss-1518	50	7	the	the	DET
ajrhss-1518	50	8	first	first	ADJ
ajrhss-1518	50	9	symptoms	symptom	NOUN
ajrhss-1518	50	10	of	of	ADP
ajrhss-1518	50	11	the	the	DET
ajrhss-1518	50	12	disease	disease	NOUN
ajrhss-1518	50	13	and	and	CCONJ
ajrhss-1518	50	14	the	the	DET
ajrhss-1518	50	15	inclusion	inclusion	NOUN
ajrhss-1518	50	16	of	of	ADP
ajrhss-1518	50	17	the	the	DET
ajrhss-1518	50	18	patient	patient	NOUN
ajrhss-1518	50	19	in	in	ADP
ajrhss-1518	50	20	the	the	DET
ajrhss-1518	50	21	study	study	NOUN
ajrhss-1518	50	22	was	be	AUX
ajrhss-1518	50	23	no	no	ADV
ajrhss-1518	50	24	more	more	ADJ
ajrhss-1518	50	25	than	than	ADP
ajrhss-1518	50	26	36	36	NUM
ajrhss-1518	50	27	hours	hour	NOUN
ajrhss-1518	50	28	.	.	PUNCT
ajrhss-1518	51	1	the	the	DET
ajrhss-1518	51	2	criteria	criterion	NOUN
ajrhss-1518	51	3	for	for	ADP
ajrhss-1518	51	4	non	non	ADJ
ajrhss-1518	51	5	-	-	ADJ
ajrhss-1518	51	6	inclusion	inclusion	NOUN
ajrhss-1518	51	7	included	include	VERB
ajrhss-1518	51	8	a	a	DET
ajrhss-1518	51	9	history	history	NOUN
ajrhss-1518	51	10	of	of	ADP
ajrhss-1518	51	11	vaccination	vaccination	NOUN
ajrhss-1518	51	12	against	against	ADP
ajrhss-1518	51	13	influenza	influenza	NOUN
ajrhss-1518	51	14	,	,	PUNCT
ajrhss-1518	51	15	sars	sar	NOUN
ajrhss-1518	51	16	-	-	PUNCT
ajrhss-1518	51	17	cov-2	cov-2	NOUN
ajrhss-1518	51	18	,	,	PUNCT
ajrhss-1518	51	19	carried	carry	VERB
ajrhss-1518	51	20	out	out	ADP
ajrhss-1518	51	21	within	within	ADP
ajrhss-1518	51	22	12	12	NUM
ajrhss-1518	51	23	months	month	NOUN
ajrhss-1518	51	24	before	before	ADP
ajrhss-1518	51	25	screening	screen	VERB
ajrhss-1518	51	26	,	,	PUNCT
ajrhss-1518	51	27	as	as	ADV
ajrhss-1518	51	28	well	well	ADV
ajrhss-1518	51	29	as	as	ADP
ajrhss-1518	51	30	a	a	DET
ajrhss-1518	51	31	positive	positive	ADJ
ajrhss-1518	51	32	pcr	pcr	ADJ
ajrhss-1518	51	33	result	result	NOUN
ajrhss-1518	51	34	for	for	ADP
ajrhss-1518	51	35	viruses	virus	NOUN
ajrhss-1518	51	36	influenza	influenza	NOUN
ajrhss-1518	51	37	and	and	CCONJ
ajrhss-1518	51	38	sars	sar	NOUN
ajrhss-1518	51	39	-	-	PUNCT
ajrhss-1518	51	40	cov-2	cov-2	NOUN
ajrhss-1518	51	41	.	.	PUNCT
ajrhss-1518	52	1	a	a	DET
ajrhss-1518	52	2	total	total	NOUN
ajrhss-1518	52	3	of	of	ADP
ajrhss-1518	52	4	132	132	NUM
ajrhss-1518	52	5	patients	patient	NOUN
ajrhss-1518	52	6	completed	complete	VERB
ajrhss-1518	52	7	the	the	DET
ajrhss-1518	52	8	study	study	NOUN
ajrhss-1518	52	9	per	per	ADP
ajrhss-1518	52	10	protocol	protocol	NOUN
ajrhss-1518	52	11	,	,	PUNCT
ajrhss-1518	52	12	including	include	VERB
ajrhss-1518	52	13	97	97	NUM
ajrhss-1518	52	14	in	in	ADP
ajrhss-1518	52	15	group	group	NOUN
ajrhss-1518	52	16	1	1	NUM
ajrhss-1518	52	17	(	(	PUNCT
ajrhss-1518	52	18	patients	patient	NOUN
ajrhss-1518	52	19	taking	take	VERB
ajrhss-1518	52	20	riamilovir	riamilovir	PRON
ajrhss-1518	52	21	)	)	PUNCT
ajrhss-1518	52	22	and	and	CCONJ
ajrhss-1518	52	23	35	35	NUM
ajrhss-1518	52	24	in	in	ADP
ajrhss-1518	52	25	group	group	NOUN
ajrhss-1518	52	26	2	2	NUM
ajrhss-1518	52	27	(	(	PUNCT
ajrhss-1518	52	28	patients	patient	NOUN
ajrhss-1518	52	29	taking	take	VERB
ajrhss-1518	52	30	placebo	placebo	NOUN
ajrhss-1518	52	31	)	)	PUNCT
ajrhss-1518	52	32	.	.	PUNCT
ajrhss-1518	53	1	randomization	randomization	NOUN
ajrhss-1518	53	2	was	be	AUX
ajrhss-1518	53	3	carried	carry	VERB
ajrhss-1518	53	4	out	out	ADP
ajrhss-1518	53	5	using	use	VERB
ajrhss-1518	53	6	the	the	DET
ajrhss-1518	53	7	envelope	envelope	NOUN
ajrhss-1518	53	8	method	method	NOUN
ajrhss-1518	53	9	.	.	PUNCT
ajrhss-1518	54	1	in	in	ADP
ajrhss-1518	54	2	phase	phase	NOUN
ajrhss-1518	54	3	i	i	PRON
ajrhss-1518	54	4	of	of	ADP
ajrhss-1518	54	5	the	the	DET
ajrhss-1518	54	6	study	study	NOUN
ajrhss-1518	54	7	,	,	PUNCT
ajrhss-1518	54	8	20	20	NUM
ajrhss-1518	54	9	patients	patient	NOUN
ajrhss-1518	54	10	participating	participate	VERB
ajrhss-1518	54	11	in	in	ADP
ajrhss-1518	54	12	the	the	DET
ajrhss-1518	54	13	pk	pk	NOUN
ajrhss-1518	54	14	portion	portion	NOUN
ajrhss-1518	54	15	of	of	ADP
ajrhss-1518	54	16	the	the	DET
ajrhss-1518	54	17	study	study	NOUN
ajrhss-1518	54	18	who	who	PRON
ajrhss-1518	54	19	met	meet	VERB
ajrhss-1518	54	20	the	the	DET
ajrhss-1518	54	21	inclusion	inclusion	NOUN
ajrhss-1518	54	22	criteria	criterion	NOUN
ajrhss-1518	54	23	in	in	ADP
ajrhss-1518	54	24	the	the	DET
ajrhss-1518	54	25	absence	absence	NOUN
ajrhss-1518	54	26	of	of	ADP
ajrhss-1518	54	27	any	any	DET
ajrhss-1518	54	28	non	non	ADJ
ajrhss-1518	54	29	-	-	NOUN
ajrhss-1518	54	30	inclusion	inclusion	ADJ
ajrhss-1518	54	31	or	or	CCONJ
ajrhss-1518	54	32	exclusion	exclusion	NOUN
ajrhss-1518	54	33	criteria	criterion	NOUN
ajrhss-1518	54	34	were	be	AUX
ajrhss-1518	54	35	randomized	randomize	VERB
ajrhss-1518	54	36	into	into	ADP
ajrhss-1518	54	37	2	2	NUM
ajrhss-1518	54	38	groups	group	NOUN
ajrhss-1518	54	39	in	in	ADP
ajrhss-1518	54	40	a	a	DET
ajrhss-1518	54	41	1:1	1:1	NUM
ajrhss-1518	54	42	ratio	ratio	NOUN
ajrhss-1518	54	43	:	:	PUNCT
ajrhss-1518	54	44	group	group	NOUN
ajrhss-1518	54	45	1	1	NUM
ajrhss-1518	54	46	(	(	PUNCT
ajrhss-1518	54	47	10	10	NUM
ajrhss-1518	54	48	patients	patient	NOUN
ajrhss-1518	54	49	)	)	PUNCT
ajrhss-1518	54	50	–	–	PUNCT
ajrhss-1518	54	51	the	the	DET
ajrhss-1518	54	52	drug	drug	NOUN
ajrhss-1518	54	53	riamilovir	riamilovir	PRON
ajrhss-1518	54	54	,	,	PUNCT
ajrhss-1518	54	55	capsules	capsule	VERB
ajrhss-1518	54	56	100	100	NUM
ajrhss-1518	54	57	mg	mg	NOUN
ajrhss-1518	54	58	,	,	PUNCT
ajrhss-1518	54	59	1st	1st	NOUN
ajrhss-1518	54	60	dose	dose	VERB
ajrhss-1518	54	61	100	100	NUM
ajrhss-1518	54	62	mg	mg	PROPN
ajrhss-1518	54	63	(	(	PUNCT
ajrhss-1518	54	64	1	1	NUM
ajrhss-1518	54	65	capsule	capsule	NOUN
ajrhss-1518	54	66	)	)	PUNCT
ajrhss-1518	54	67	,	,	PUNCT
ajrhss-1518	54	68	then	then	ADV
ajrhss-1518	54	69	therapy	therapy	NOUN
ajrhss-1518	54	70	according	accord	VERB
ajrhss-1518	54	71	to	to	ADP
ajrhss-1518	54	72	the	the	DET
ajrhss-1518	54	73	regimen	regimen	NOUN
ajrhss-1518	54	74	corresponding	correspond	VERB
ajrhss-1518	54	75	to	to	ADP
ajrhss-1518	54	76	group	group	NOUN
ajrhss-1518	54	77	i	i	PRON
ajrhss-1518	54	78	(	(	PUNCT
ajrhss-1518	54	79	3	3	NUM
ajrhss-1518	54	80	times	time	NOUN
ajrhss-1518	54	81	a	a	DET
ajrhss-1518	54	82	day	day	NOUN
ajrhss-1518	54	83	,	,	PUNCT
ajrhss-1518	54	84	1	1	NUM
ajrhss-1518	54	85	capsule	capsule	NOUN
ajrhss-1518	54	86	and	and	CCONJ
ajrhss-1518	54	87	2	2	NUM
ajrhss-1518	54	88	capsules	capsule	NOUN
ajrhss-1518	54	89	1	1	NUM
ajrhss-1518	54	90	time	time	NOUN
ajrhss-1518	54	91	at	at	ADP
ajrhss-1518	54	92	night	night	NOUN
ajrhss-1518	54	93	at	at	ADP
ajrhss-1518	54	94	within	within	ADP
ajrhss-1518	54	95	5	5	NUM
ajrhss-1518	54	96	days	day	NOUN
ajrhss-1518	54	97	)	)	PUNCT
ajrhss-1518	54	98	;	;	PUNCT
ajrhss-1518	54	99	group	group	NOUN
ajrhss-1518	54	100	2	2	NUM
ajrhss-1518	54	101	(	(	PUNCT
ajrhss-1518	54	102	10	10	NUM
ajrhss-1518	54	103	patients	patient	NOUN
ajrhss-1518	54	104	)	)	PUNCT
ajrhss-1518	54	105	the	the	DET
ajrhss-1518	54	106	drug	drug	NOUN
ajrhss-1518	54	107	riamilovir	riamilovir	PRON
ajrhss-1518	54	108	,	,	PUNCT
ajrhss-1518	54	109	capsules	capsule	VERB
ajrhss-1518	54	110	100	100	NUM
ajrhss-1518	54	111	mg	mg	NOUN
ajrhss-1518	54	112	,	,	PUNCT
ajrhss-1518	54	113	1st	1st	NOUN
ajrhss-1518	54	114	dose	dose	VERB
ajrhss-1518	54	115	200	200	NUM
ajrhss-1518	54	116	mg	mg	PROPN
ajrhss-1518	54	117	(	(	PUNCT
ajrhss-1518	54	118	2	2	NUM
ajrhss-1518	54	119	capsules	capsule	NOUN
ajrhss-1518	54	120	)	)	PUNCT
ajrhss-1518	54	121	,	,	PUNCT
ajrhss-1518	54	122	then	then	ADV
ajrhss-1518	54	123	therapy	therapy	NOUN
ajrhss-1518	54	124	according	accord	VERB
ajrhss-1518	54	125	to	to	ADP
ajrhss-1518	54	126	the	the	DET
ajrhss-1518	54	127	regimen	regimen	NOUN
ajrhss-1518	54	128	corresponding	correspond	VERB
ajrhss-1518	54	129	to	to	ADP
ajrhss-1518	54	130	group	group	NOUN
ajrhss-1518	54	131	i	i	PRON
ajrhss-1518	54	132	(	(	PUNCT
ajrhss-1518	54	133	3	3	NUM
ajrhss-1518	54	134	times	time	NOUN
ajrhss-1518	54	135	a	a	DET
ajrhss-1518	54	136	day	day	NOUN
ajrhss-1518	54	137	,	,	PUNCT
ajrhss-1518	54	138	1	1	NUM
ajrhss-1518	54	139	capsule	capsule	NOUN
ajrhss-1518	54	140	and	and	CCONJ
ajrhss-1518	54	141	2	2	NUM
ajrhss-1518	54	142	capsules	capsule	NOUN
ajrhss-1518	54	143	1	1	NUM
ajrhss-1518	54	144	time	time	NOUN
ajrhss-1518	54	145	at	at	ADP
ajrhss-1518	54	146	night	night	NOUN
ajrhss-1518	54	147	at	at	ADP
ajrhss-1518	54	148	within	within	ADP
ajrhss-1518	54	149	5	5	NUM
ajrhss-1518	54	150	days	day	NOUN
ajrhss-1518	54	151	)	)	PUNCT
ajrhss-1518	54	152	.	.	PUNCT
ajrhss-1518	55	1	at	at	ADP
ajrhss-1518	55	2	stage	stage	NOUN
ajrhss-1518	55	3	ii	ii	PROPN
ajrhss-1518	55	4	of	of	ADP
ajrhss-1518	55	5	the	the	DET
ajrhss-1518	55	6	study	study	NOUN
ajrhss-1518	55	7	,	,	PUNCT
ajrhss-1518	55	8	the	the	DET
ajrhss-1518	55	9	remaining	remain	VERB
ajrhss-1518	55	10	patients	patient	NOUN
ajrhss-1518	55	11	were	be	AUX
ajrhss-1518	55	12	randomized	randomize	VERB
ajrhss-1518	55	13	into	into	ADP
ajrhss-1518	55	14	2	2	NUM
ajrhss-1518	55	15	groups	group	NOUN
ajrhss-1518	55	16	:	:	PUNCT
ajrhss-1518	55	17	group	group	NOUN
ajrhss-1518	55	18	i	i	PRON
ajrhss-1518	55	19	–	–	PUNCT
ajrhss-1518	55	20	riamilovir	riamilovir	ADV
ajrhss-1518	55	21	,	,	PUNCT
ajrhss-1518	55	22	capsules	capsule	VERB
ajrhss-1518	55	23	100	100	NUM
ajrhss-1518	55	24	mg	mg	NOUN
ajrhss-1518	55	25	,	,	PUNCT
ajrhss-1518	55	26	1	1	NUM
ajrhss-1518	55	27	capsule	capsule	NOUN
ajrhss-1518	55	28	3	3	NUM
ajrhss-1518	55	29	times	time	NOUN
ajrhss-1518	55	30	a	a	DET
ajrhss-1518	55	31	day	day	NOUN
ajrhss-1518	55	32	and	and	CCONJ
ajrhss-1518	55	33	2	2	NUM
ajrhss-1518	55	34	capsules	capsule	NOUN
ajrhss-1518	55	35	at	at	ADP
ajrhss-1518	55	36	night	night	NOUN
ajrhss-1518	55	37	(	(	PUNCT
ajrhss-1518	55	38	daily	daily	PROPN
ajrhss-1518	55	39	dose	dose	NOUN
ajrhss-1518	55	40	of	of	ADP
ajrhss-1518	55	41	the	the	DET
ajrhss-1518	55	42	study	study	NOUN
ajrhss-1518	55	43	drug	drug	NOUN
ajrhss-1518	55	44	500	500	NUM
ajrhss-1518	55	45	mg	mg	PROPN
ajrhss-1518	55	46	,	,	PUNCT
ajrhss-1518	55	47	course	course	NOUN
ajrhss-1518	55	48	dose	dose	VERB
ajrhss-1518	55	49	2500	2500	NUM
ajrhss-1518	55	50	mg	mg	NOUN
ajrhss-1518	55	51	)	)	PUNCT
ajrhss-1518	55	52	for	for	ADP
ajrhss-1518	55	53	5	5	NUM
ajrhss-1518	55	54	days	day	NOUN
ajrhss-1518	55	55	;	;	PUNCT
ajrhss-1518	55	56	group	group	NOUN
ajrhss-1518	55	57	ii	ii	PROPN
ajrhss-1518	55	58	–	–	PUNCT
ajrhss-1518	55	59	placebo	placebo	NOUN
ajrhss-1518	55	60	,	,	PUNCT
ajrhss-1518	55	61	1	1	NUM
ajrhss-1518	55	62	capsule	capsule	NOUN
ajrhss-1518	55	63	3	3	NUM
ajrhss-1518	55	64	times	time	NOUN
ajrhss-1518	55	65	a	a	DET
ajrhss-1518	55	66	day	day	NOUN
ajrhss-1518	55	67	and	and	CCONJ
ajrhss-1518	55	68	2	2	NUM
ajrhss-1518	55	69	capsules	capsule	NOUN
ajrhss-1518	55	70	at	at	ADP
ajrhss-1518	55	71	night	night	NOUN
ajrhss-1518	55	72	,	,	PUNCT
ajrhss-1518	55	73	for	for	ADP
ajrhss-1518	55	74	5	5	NUM
ajrhss-1518	55	75	days	day	NOUN
ajrhss-1518	55	76	.	.	PUNCT
ajrhss-1518	56	1	the	the	DET
ajrhss-1518	56	2	effectiveness	effectiveness	NOUN
ajrhss-1518	56	3	was	be	AUX
ajrhss-1518	56	4	assessed	assess	VERB
ajrhss-1518	56	5	based	base	VERB
ajrhss-1518	56	6	on	on	ADP
ajrhss-1518	56	7	the	the	DET
ajrhss-1518	56	8	analysis	analysis	NOUN
ajrhss-1518	56	9	of	of	ADP
ajrhss-1518	56	10	primary	primary	ADJ
ajrhss-1518	56	11	and	and	CCONJ
ajrhss-1518	56	12	secondary	secondary	ADJ
ajrhss-1518	56	13	endpoints	endpoint	NOUN
ajrhss-1518	56	14	in	in	ADP
ajrhss-1518	56	15	patients	patient	NOUN
ajrhss-1518	56	16	with	with	ADP
ajrhss-1518	56	17	arvi	arvi	NOUN
ajrhss-1518	56	18	(	(	PUNCT
ajrhss-1518	56	19	with	with	ADP
ajrhss-1518	56	20	laboratory	laboratory	NOUN
ajrhss-1518	56	21	-	-	PUNCT
ajrhss-1518	56	22	confirmed	confirm	VERB
ajrhss-1518	56	23	presence	presence	NOUN
ajrhss-1518	56	24	of	of	ADP
ajrhss-1518	56	25	rna	rna	PROPN
ajrhss-1518	56	26	/	/	SYM
ajrhss-1518	56	27	dna	dna	PROPN
ajrhss-1518	56	28	virus	virus	NOUN
ajrhss-1518	56	29	by	by	ADP
ajrhss-1518	56	30	pcr	pcr	ADJ
ajrhss-1518	56	31	method	method	NOUN
ajrhss-1518	56	32	,	,	PUNCT
ajrhss-1518	56	33	absence	absence	NOUN
ajrhss-1518	56	34	of	of	ADP
ajrhss-1518	56	35	influenza	influenza	NOUN
ajrhss-1518	56	36	virus	virus	NOUN
ajrhss-1518	56	37	and	and	CCONJ
ajrhss-1518	56	38	sars	sar	NOUN
ajrhss-1518	56	39	-	-	PUNCT
ajrhss-1518	56	40	cov-2	cov-2	NOUN
ajrhss-1518	56	41	markers	marker	NOUN
ajrhss-1518	56	42	)	)	PUNCT
ajrhss-1518	56	43	who	who	PRON
ajrhss-1518	56	44	took	take	VERB
ajrhss-1518	56	45	the	the	DET
ajrhss-1518	56	46	drug	drug	NOUN
ajrhss-1518	56	47	at	at	ADP
ajrhss-1518	56	48	least	least	ADJ
ajrhss-1518	56	49	once	once	ADV
ajrhss-1518	56	50	and	and	CCONJ
ajrhss-1518	56	51	met	meet	VERB
ajrhss-1518	56	52	the	the	DET
ajrhss-1518	56	53	selection	selection	NOUN
ajrhss-1518	56	54	criteria	criterion	NOUN
ajrhss-1518	56	55	.	.	PUNCT
ajrhss-1518	57	1	the	the	DET
ajrhss-1518	57	2	primary	primary	ADJ
ajrhss-1518	57	3	end	end	NOUN
ajrhss-1518	57	4	point	point	NOUN
ajrhss-1518	57	5	was	be	AUX
ajrhss-1518	57	6	the	the	DET
ajrhss-1518	57	7	time	time	NOUN
ajrhss-1518	57	8	until	until	ADP
ajrhss-1518	57	9	the	the	DET
ajrhss-1518	57	10	onset	onset	NOUN
ajrhss-1518	57	11	of	of	ADP
ajrhss-1518	57	12	persistent	persistent	ADJ
ajrhss-1518	57	13	improvement	improvement	NOUN
ajrhss-1518	57	14	in	in	ADP
ajrhss-1518	57	15	clinical	clinical	ADJ
ajrhss-1518	57	16	symptoms	symptom	NOUN
ajrhss-1518	57	17	on	on	ADP
ajrhss-1518	57	18	the	the	DET
ajrhss-1518	57	19	severity	severity	NOUN
ajrhss-1518	57	20	scale	scale	NOUN
ajrhss-1518	57	21	for	for	ADP
ajrhss-1518	57	22	acute	acute	ADJ
ajrhss-1518	57	23	respiratory	respiratory	ADJ
ajrhss-1518	57	24	viral	viral	ADJ
ajrhss-1518	57	25	infections	infection	NOUN
ajrhss-1518	57	26	(	(	PUNCT
ajrhss-1518	57	27	less	less	ADJ
ajrhss-1518	57	28	than	than	ADP
ajrhss-1518	57	29	or	or	CCONJ
ajrhss-1518	57	30	equal	equal	ADJ
ajrhss-1518	57	31	to	to	ADP
ajrhss-1518	57	32	2	2	NUM
ajrhss-1518	57	33	points	point	NOUN
ajrhss-1518	57	34	,	,	PUNCT
ajrhss-1518	57	35	provided	provide	VERB
ajrhss-1518	57	36	there	there	PRON
ajrhss-1518	57	37	is	be	VERB
ajrhss-1518	57	38	no	no	DET
ajrhss-1518	57	39	more	more	ADJ
ajrhss-1518	57	40	than	than	ADP
ajrhss-1518	57	41	1	1	NUM
ajrhss-1518	57	42	point	point	NOUN
ajrhss-1518	57	43	for	for	ADP
ajrhss-1518	57	44	1	1	NUM
ajrhss-1518	57	45	symptom	symptom	NOUN
ajrhss-1518	57	46	)	)	PUNCT
ajrhss-1518	57	47	with	with	ADP
ajrhss-1518	57	48	normalization	normalization	NOUN
ajrhss-1518	57	49	of	of	ADP
ajrhss-1518	57	50	temperature	temperature	NOUN
ajrhss-1518	57	51	(	(	PUNCT
ajrhss-1518	57	52	less	less	ADJ
ajrhss-1518	57	53	than	than	ADP
ajrhss-1518	57	54	37	37	NUM
ajrhss-1518	57	55	°	°	NOUN
ajrhss-1518	57	56	c	c	NOUN
ajrhss-1518	57	57	)	)	PUNCT
ajrhss-1518	57	58	;	;	PUNCT
ajrhss-1518	57	59	persistent	persistent	ADJ
ajrhss-1518	57	60	improvement	improvement	NOUN
ajrhss-1518	57	61	means	mean	VERB
ajrhss-1518	57	62	maintenance	maintenance	NOUN
ajrhss-1518	57	63	symptoms	symptom	NOUN
ajrhss-1518	57	64	improve	improve	VERB
ajrhss-1518	57	65	for	for	ADP
ajrhss-1518	57	66	at	at	ADV
ajrhss-1518	57	67	least	least	ADV
ajrhss-1518	57	68	22	22	NUM
ajrhss-1518	57	69	hours	hour	NOUN
ajrhss-1518	57	70	.	.	PUNCT
ajrhss-1518	58	1	secondary	secondary	ADJ
ajrhss-1518	58	2	endpoints	endpoint	NOUN
ajrhss-1518	58	3	:	:	PUNCT
ajrhss-1518	58	4	area	area	NOUN
ajrhss-1518	58	5	under	under	ADP
ajrhss-1518	58	6	the	the	DET
ajrhss-1518	58	7	curve	curve	NOUN
ajrhss-1518	58	8	“	"	PUNCT
ajrhss-1518	58	9	score	score	NOUN
ajrhss-1518	58	10	on	on	ADP
ajrhss-1518	58	11	the	the	DET
ajrhss-1518	58	12	scale	scale	NOUN
ajrhss-1518	58	13	of	of	ADP
ajrhss-1518	58	14	severity	severity	NOUN
ajrhss-1518	58	15	of	of	ADP
ajrhss-1518	58	16	the	the	DET
ajrhss-1518	58	17	patient	patient	NOUN
ajrhss-1518	58	18	’s	’s	PART
ajrhss-1518	58	19	condition	condition	NOUN
ajrhss-1518	58	20	with	with	ADP
ajrhss-1518	58	21	arvi	arvi	ADJ
ajrhss-1518	58	22	time	time	NOUN
ajrhss-1518	58	23	”	"	PUNCT
ajrhss-1518	58	24	during	during	ADP
ajrhss-1518	58	25	5	5	NUM
ajrhss-1518	58	26	days	day	NOUN
ajrhss-1518	58	27	of	of	ADP
ajrhss-1518	58	28	therapy	therapy	NOUN
ajrhss-1518	58	29	;	;	PUNCT
ajrhss-1518	58	30	american	american	PROPN
ajrhss-1518	58	31	journal	journal	PROPN
ajrhss-1518	58	32	of	of	ADP
ajrhss-1518	58	33	research	research	NOUN
ajrhss-1518	58	34	in	in	ADP
ajrhss-1518	58	35	humanities	humanity	NOUN
ajrhss-1518	58	36	and	and	CCONJ
ajrhss-1518	58	37	social	social	ADJ
ajrhss-1518	58	38	sciences	science	NOUN
ajrhss-1518	58	39	volume	volume	NOUN
ajrhss-1518	58	40	18	18	NUM
ajrhss-1518	58	41	nov	nov	PROPN
ajrhss-1518	58	42	.	.	PROPN
ajrhss-1518	58	43	,	,	PUNCT
ajrhss-1518	58	44	2023	2023	NUM
ajrhss-1518	58	45	p	p	NOUN
ajrhss-1518	58	46	a	a	DET
ajrhss-1518	58	47	g	g	NOUN
ajrhss-1518	58	48	e	e	NOUN
ajrhss-1518	58	49	|	|	ADV
ajrhss-1518	58	50	139	139	NUM
ajrhss-1518	58	51	www.americanjournal.org	www.americanjournal.org	NOUN
ajrhss-1518	58	52	time	time	NOUN
ajrhss-1518	58	53	until	until	SCONJ
ajrhss-1518	58	54	body	body	NOUN
ajrhss-1518	58	55	temperature	temperature	NOUN
ajrhss-1518	58	56	normalizes	normalize	VERB
ajrhss-1518	58	57	from	from	ADP
ajrhss-1518	58	58	the	the	DET
ajrhss-1518	58	59	moment	moment	NOUN
ajrhss-1518	58	60	the	the	DET
ajrhss-1518	58	61	first	first	ADJ
ajrhss-1518	58	62	symptoms	symptom	NOUN
ajrhss-1518	58	63	of	of	ADP
ajrhss-1518	58	64	the	the	DET
ajrhss-1518	58	65	disease	disease	NOUN
ajrhss-1518	58	66	appear	appear	VERB
ajrhss-1518	58	67	,	,	PUNCT
ajrhss-1518	58	68	measured	measure	VERB
ajrhss-1518	58	69	in	in	ADP
ajrhss-1518	58	70	hours	hour	NOUN
ajrhss-1518	58	71	(	(	PUNCT
ajrhss-1518	58	72	normalization	normalization	NOUN
ajrhss-1518	58	73	means	mean	VERB
ajrhss-1518	58	74	setting	set	VERB
ajrhss-1518	58	75	the	the	DET
ajrhss-1518	58	76	temperature	temperature	NOUN
ajrhss-1518	58	77	below	below	ADP
ajrhss-1518	58	78	37	37	NUM
ajrhss-1518	58	79	°	°	ADP
ajrhss-1518	58	80	c	c	NOUN
ajrhss-1518	58	81	without	without	ADP
ajrhss-1518	58	82	rising	rise	VERB
ajrhss-1518	58	83	above	above	ADP
ajrhss-1518	58	84	these	these	DET
ajrhss-1518	58	85	values	value	NOUN
ajrhss-1518	58	86	in	in	ADP
ajrhss-1518	58	87	the	the	DET
ajrhss-1518	58	88	subsequent	subsequent	ADJ
ajrhss-1518	58	89	period	period	NOUN
ajrhss-1518	58	90	)	)	PUNCT
ajrhss-1518	58	91	;	;	PUNCT
ajrhss-1518	58	92	time	time	NOUN
ajrhss-1518	58	93	until	until	ADP
ajrhss-1518	58	94	the	the	DET
ajrhss-1518	58	95	disappearance	disappearance	NOUN
ajrhss-1518	58	96	of	of	ADP
ajrhss-1518	58	97	all	all	DET
ajrhss-1518	58	98	symptoms	symptom	NOUN
ajrhss-1518	58	99	according	accord	VERB
ajrhss-1518	58	100	to	to	ADP
ajrhss-1518	58	101	the	the	DET
ajrhss-1518	58	102	severity	severity	NOUN
ajrhss-1518	58	103	rating	rating	NOUN
ajrhss-1518	58	104	scale	scale	NOUN
ajrhss-1518	58	105	for	for	ADP
ajrhss-1518	58	106	arvi	arvi	NOUN
ajrhss-1518	58	107	from	from	ADP
ajrhss-1518	58	108	the	the	DET
ajrhss-1518	58	109	moment	moment	NOUN
ajrhss-1518	58	110	the	the	DET
ajrhss-1518	58	111	first	first	ADJ
ajrhss-1518	58	112	symptoms	symptom	NOUN
ajrhss-1518	58	113	of	of	ADP
ajrhss-1518	58	114	the	the	DET
ajrhss-1518	58	115	disease	disease	NOUN
ajrhss-1518	58	116	appear	appear	VERB
ajrhss-1518	58	117	;	;	PUNCT
ajrhss-1518	58	118	the	the	DET
ajrhss-1518	58	119	proportion	proportion	NOUN
ajrhss-1518	58	120	of	of	ADP
ajrhss-1518	58	121	patients	patient	NOUN
ajrhss-1518	58	122	with	with	ADP
ajrhss-1518	58	123	normalization	normalization	NOUN
ajrhss-1518	58	124	of	of	ADP
ajrhss-1518	58	125	body	body	NOUN
ajrhss-1518	58	126	temperature	temperature	NOUN
ajrhss-1518	58	127	below	below	ADP
ajrhss-1518	58	128	37	37	NUM
ajrhss-1518	58	129	°	°	NOUN
ajrhss-1518	58	130	c	c	NOUN
ajrhss-1518	58	131	by	by	ADP
ajrhss-1518	58	132	1	1	NUM
ajrhss-1518	58	133	,	,	PUNCT
ajrhss-1518	58	134	2	2	NUM
ajrhss-1518	58	135	,	,	PUNCT
ajrhss-1518	58	136	3	3	NUM
ajrhss-1518	58	137	,	,	PUNCT
ajrhss-1518	58	138	4	4	NUM
ajrhss-1518	58	139	,	,	PUNCT
ajrhss-1518	58	140	5	5	NUM
ajrhss-1518	58	141	,	,	PUNCT
ajrhss-1518	58	142	6	6	NUM
ajrhss-1518	58	143	,	,	PUNCT
ajrhss-1518	58	144	7	7	NUM
ajrhss-1518	58	145	and	and	CCONJ
ajrhss-1518	58	146	8	8	NUM
ajrhss-1518	58	147	days	day	NOUN
ajrhss-1518	58	148	from	from	ADP
ajrhss-1518	58	149	the	the	DET
ajrhss-1518	58	150	onset	onset	NOUN
ajrhss-1518	58	151	of	of	ADP
ajrhss-1518	58	152	the	the	DET
ajrhss-1518	58	153	first	first	ADJ
ajrhss-1518	58	154	symptoms	symptom	NOUN
ajrhss-1518	58	155	of	of	ADP
ajrhss-1518	58	156	the	the	DET
ajrhss-1518	58	157	disease	disease	NOUN
ajrhss-1518	58	158	;	;	PUNCT
ajrhss-1518	58	159	the	the	DET
ajrhss-1518	58	160	proportion	proportion	NOUN
ajrhss-1518	58	161	of	of	ADP
ajrhss-1518	58	162	patients	patient	NOUN
ajrhss-1518	58	163	with	with	ADP
ajrhss-1518	58	164	complete	complete	ADJ
ajrhss-1518	58	165	disappearance	disappearance	NOUN
ajrhss-1518	58	166	of	of	ADP
ajrhss-1518	58	167	all	all	DET
ajrhss-1518	58	168	symptoms	symptom	NOUN
ajrhss-1518	58	169	by	by	ADP
ajrhss-1518	58	170	1	1	NUM
ajrhss-1518	58	171	,	,	PUNCT
ajrhss-1518	58	172	2	2	NUM
ajrhss-1518	58	173	,	,	PUNCT
ajrhss-1518	58	174	3	3	NUM
ajrhss-1518	58	175	,	,	PUNCT
ajrhss-1518	58	176	4	4	NUM
ajrhss-1518	58	177	,	,	PUNCT
ajrhss-1518	58	178	5	5	NUM
ajrhss-1518	58	179	,	,	PUNCT
ajrhss-1518	58	180	6	6	NUM
ajrhss-1518	58	181	,	,	PUNCT
ajrhss-1518	58	182	7	7	NUM
ajrhss-1518	58	183	and	and	CCONJ
ajrhss-1518	58	184	8	8	NUM
ajrhss-1518	58	185	days	day	NOUN
ajrhss-1518	58	186	from	from	ADP
ajrhss-1518	58	187	the	the	DET
ajrhss-1518	58	188	onset	onset	NOUN
ajrhss-1518	58	189	of	of	ADP
ajrhss-1518	58	190	the	the	DET
ajrhss-1518	58	191	first	first	ADJ
ajrhss-1518	58	192	symptoms	symptom	NOUN
ajrhss-1518	58	193	of	of	ADP
ajrhss-1518	58	194	the	the	DET
ajrhss-1518	58	195	disease	disease	NOUN
ajrhss-1518	58	196	;	;	PUNCT
ajrhss-1518	58	197	-average	-average	ADJ
ajrhss-1518	58	198	body	body	NOUN
ajrhss-1518	58	199	temperature	temperature	NOUN
ajrhss-1518	58	200	at	at	ADP
ajrhss-1518	58	201	1	1	NUM
ajrhss-1518	58	202	,	,	PUNCT
ajrhss-1518	58	203	2	2	NUM
ajrhss-1518	58	204	,	,	PUNCT
ajrhss-1518	58	205	3	3	NUM
ajrhss-1518	58	206	,	,	PUNCT
ajrhss-1518	58	207	4	4	NUM
ajrhss-1518	58	208	,	,	PUNCT
ajrhss-1518	58	209	5	5	NUM
ajrhss-1518	58	210	,	,	PUNCT
ajrhss-1518	58	211	6	6	NUM
ajrhss-1518	58	212	,	,	PUNCT
ajrhss-1518	58	213	7	7	NUM
ajrhss-1518	58	214	and	and	CCONJ
ajrhss-1518	58	215	8	8	NUM
ajrhss-1518	58	216	days	day	NOUN
ajrhss-1518	58	217	from	from	ADP
ajrhss-1518	58	218	time	time	NOUN
ajrhss-1518	58	219	from	from	ADP
ajrhss-1518	58	220	the	the	DET
ajrhss-1518	58	221	moment	moment	NOUN
ajrhss-1518	58	222	of	of	ADP
ajrhss-1518	58	223	appearance	appearance	NOUN
ajrhss-1518	58	224	to	to	ADP
ajrhss-1518	58	225	the	the	DET
ajrhss-1518	58	226	disappearance	disappearance	NOUN
ajrhss-1518	58	227	of	of	ADP
ajrhss-1518	58	228	catarrhal	catarrhal	ADJ
ajrhss-1518	58	229	-	-	PUNCT
ajrhss-1518	58	230	respiratory	respiratory	ADJ
ajrhss-1518	58	231	syndrome	syndrome	NOUN
ajrhss-1518	58	232	,	,	PUNCT
ajrhss-1518	58	233	including	include	VERB
ajrhss-1518	58	234	sore	sore	ADJ
ajrhss-1518	58	235	throat	throat	NOUN
ajrhss-1518	58	236	,	,	PUNCT
ajrhss-1518	58	237	cough	cough	NOUN
ajrhss-1518	58	238	,	,	PUNCT
ajrhss-1518	58	239	hoarseness	hoarseness	NOUN
ajrhss-1518	58	240	,	,	PUNCT
ajrhss-1518	58	241	sneezing	sneeze	VERB
ajrhss-1518	58	242	,	,	PUNCT
ajrhss-1518	58	243	runny	runny	ADJ
ajrhss-1518	58	244	nose	nose	NOUN
ajrhss-1518	58	245	,	,	PUNCT
ajrhss-1518	58	246	nasal	nasal	PROPN
ajrhss-1518	58	247	congestion	congestion	NOUN
ajrhss-1518	58	248	(	(	PUNCT
ajrhss-1518	58	249	according	accord	VERB
ajrhss-1518	58	250	to	to	ADP
ajrhss-1518	58	251	the	the	DET
ajrhss-1518	58	252	arvi	arvi	PROPN
ajrhss-1518	58	253	severity	severity	NOUN
ajrhss-1518	58	254	scale	scale	NOUN
ajrhss-1518	58	255	)	)	PUNCT
ajrhss-1518	58	256	,	,	PUNCT
ajrhss-1518	58	257	in	in	ADP
ajrhss-1518	58	258	a	a	DET
ajrhss-1518	58	259	population	population	NOUN
ajrhss-1518	58	260	of	of	ADP
ajrhss-1518	58	261	patients	patient	NOUN
ajrhss-1518	58	262	who	who	PRON
ajrhss-1518	58	263	exhibited	exhibit	VERB
ajrhss-1518	58	264	the	the	DET
ajrhss-1518	58	265	corresponding	correspond	VERB
ajrhss-1518	58	266	symptoms	symptom	NOUN
ajrhss-1518	58	267	;	;	PUNCT
ajrhss-1518	58	268	results	result	NOUN
ajrhss-1518	58	269	at	at	ADP
ajrhss-1518	58	270	the	the	DET
ajrhss-1518	58	271	screening	screening	NOUN
ajrhss-1518	58	272	stage	stage	NOUN
ajrhss-1518	58	273	,	,	PUNCT
ajrhss-1518	58	274	rna	rna	PROPN
ajrhss-1518	58	275	/	/	SYM
ajrhss-1518	58	276	dna	dna	NOUN
ajrhss-1518	58	277	of	of	ADP
ajrhss-1518	58	278	the	the	DET
ajrhss-1518	58	279	following	follow	VERB
ajrhss-1518	58	280	viruses	virus	NOUN
ajrhss-1518	58	281	was	be	AUX
ajrhss-1518	58	282	isolated	isolate	VERB
ajrhss-1518	58	283	:	:	PUNCT
ajrhss-1518	58	284	rhinovirus	rhinovirus	NOUN
ajrhss-1518	58	285	,	,	PUNCT
ajrhss-1518	58	286	adenovirus	adenovirus	NOUN
ajrhss-1518	58	287	,	,	PUNCT
ajrhss-1518	58	288	respiratory	respiratory	ADJ
ajrhss-1518	58	289	syncytial	syncytial	ADJ
ajrhss-1518	58	290	virus	virus	NOUN
ajrhss-1518	58	291	,	,	PUNCT
ajrhss-1518	58	292	parainfluenza	parainfluenza	PROPN
ajrhss-1518	58	293	virus	virus	PROPN
ajrhss-1518	58	294	,	,	PUNCT
ajrhss-1518	58	295	bocavirus	bocavirus	NOUN
ajrhss-1518	58	296	,	,	PUNCT
ajrhss-1518	58	297	coronavirus	coronavirus	NOUN
ajrhss-1518	58	298	hcov-229e	hcov-229e	PROPN
ajrhss-1518	58	299	,	,	PUNCT
ajrhss-1518	58	300	human	human	ADJ
ajrhss-1518	58	301	metapneumovirus	metapneumovirus	NOUN
ajrhss-1518	58	302	and	and	CCONJ
ajrhss-1518	58	303	their	their	PRON
ajrhss-1518	58	304	combinations	combination	NOUN
ajrhss-1518	58	305	.	.	PUNCT
ajrhss-1518	59	1	the	the	DET
ajrhss-1518	59	2	detailed	detailed	ADJ
ajrhss-1518	59	3	distribution	distribution	NOUN
ajrhss-1518	59	4	of	of	ADP
ajrhss-1518	59	5	detected	detect	VERB
ajrhss-1518	59	6	viruses	virus	NOUN
ajrhss-1518	59	7	is	be	AUX
ajrhss-1518	59	8	presented	present	VERB
ajrhss-1518	59	9	.	.	PUNCT
ajrhss-1518	60	1	by	by	ADP
ajrhss-1518	60	2	the	the	DET
ajrhss-1518	60	3	end	end	NOUN
ajrhss-1518	60	4	of	of	ADP
ajrhss-1518	60	5	therapy	therapy	NOUN
ajrhss-1518	60	6	,	,	PUNCT
ajrhss-1518	60	7	no	no	DET
ajrhss-1518	60	8	arvi	arvi	NOUN
ajrhss-1518	60	9	virus	virus	NOUN
ajrhss-1518	60	10	antigens	antigen	NOUN
ajrhss-1518	60	11	were	be	AUX
ajrhss-1518	60	12	detected	detect	VERB
ajrhss-1518	60	13	by	by	ADP
ajrhss-1518	60	14	pcr	pcr	PROPN
ajrhss-1518	60	15	.	.	PUNCT
ajrhss-1518	61	1	between	between	ADP
ajrhss-1518	61	2	stages	stage	NOUN
ajrhss-1518	61	3	i	i	PRON
ajrhss-1518	61	4	and	and	CCONJ
ajrhss-1518	61	5	ii	ii	PROPN
ajrhss-1518	61	6	,	,	PUNCT
ajrhss-1518	61	7	an	an	DET
ajrhss-1518	61	8	interim	interim	ADJ
ajrhss-1518	61	9	analysis	analysis	NOUN
ajrhss-1518	61	10	of	of	ADP
ajrhss-1518	61	11	preliminary	preliminary	ADJ
ajrhss-1518	61	12	safety	safety	NOUN
ajrhss-1518	61	13	data	datum	NOUN
ajrhss-1518	61	14	and	and	CCONJ
ajrhss-1518	61	15	pk	pk	NOUN
ajrhss-1518	61	16	of	of	ADP
ajrhss-1518	61	17	the	the	DET
ajrhss-1518	61	18	drug	drug	NOUN
ajrhss-1518	61	19	was	be	AUX
ajrhss-1518	61	20	carried	carry	VERB
ajrhss-1518	61	21	out	out	ADP
ajrhss-1518	61	22	.	.	PUNCT
ajrhss-1518	62	1	after	after	ADP
ajrhss-1518	62	2	receiving	receive	VERB
ajrhss-1518	62	3	positive	positive	ADJ
ajrhss-1518	62	4	findings	finding	NOUN
ajrhss-1518	62	5	from	from	ADP
ajrhss-1518	62	6	the	the	DET
ajrhss-1518	62	7	interim	interim	ADJ
ajrhss-1518	62	8	analysis	analysis	NOUN
ajrhss-1518	62	9	,	,	PUNCT
ajrhss-1518	62	10	which	which	PRON
ajrhss-1518	62	11	,	,	PUNCT
ajrhss-1518	62	12	in	in	ADP
ajrhss-1518	62	13	the	the	DET
ajrhss-1518	62	14	opinion	opinion	NOUN
ajrhss-1518	62	15	of	of	ADP
ajrhss-1518	62	16	the	the	DET
ajrhss-1518	62	17	independent	independent	ADJ
ajrhss-1518	62	18	clinical	clinical	ADJ
ajrhss-1518	62	19	trial	trial	NOUN
ajrhss-1518	62	20	data	datum	NOUN
ajrhss-1518	62	21	monitoring	monitoring	NOUN
ajrhss-1518	62	22	committee	committee	NOUN
ajrhss-1518	62	23	,	,	PUNCT
ajrhss-1518	62	24	confirmed	confirm	VERB
ajrhss-1518	62	25	the	the	DET
ajrhss-1518	62	26	feasibility	feasibility	NOUN
ajrhss-1518	62	27	of	of	ADP
ajrhss-1518	62	28	using	use	VERB
ajrhss-1518	62	29	the	the	DET
ajrhss-1518	62	30	proposed	propose	VERB
ajrhss-1518	62	31	dose	dose	NOUN
ajrhss-1518	62	32	and	and	CCONJ
ajrhss-1518	62	33	regimen	regiman	NOUN
ajrhss-1518	62	34	in	in	ADP
ajrhss-1518	62	35	children	child	NOUN
ajrhss-1518	62	36	,	,	PUNCT
ajrhss-1518	62	37	the	the	DET
ajrhss-1518	62	38	study	study	NOUN
ajrhss-1518	62	39	moved	move	VERB
ajrhss-1518	62	40	to	to	PART
ajrhss-1518	62	41	phase	phase	NOUN
ajrhss-1518	62	42	ii	ii	PROPN
ajrhss-1518	62	43	.	.	PUNCT
ajrhss-1518	63	1	thus	thus	ADV
ajrhss-1518	63	2	,	,	PUNCT
ajrhss-1518	63	3	the	the	DET
ajrhss-1518	63	4	hypothesis	hypothesis	NOUN
ajrhss-1518	63	5	about	about	ADP
ajrhss-1518	63	6	the	the	DET
ajrhss-1518	63	7	superiority	superiority	NOUN
ajrhss-1518	63	8	of	of	ADP
ajrhss-1518	63	9	the	the	DET
ajrhss-1518	63	10	drug	drug	NOUN
ajrhss-1518	63	11	riamilovir	riamilovir	PRON
ajrhss-1518	63	12	over	over	ADP
ajrhss-1518	63	13	placebo	placebo	NOUN
ajrhss-1518	63	14	was	be	AUX
ajrhss-1518	63	15	confirmed	confirm	VERB
ajrhss-1518	63	16	,	,	PUNCT
ajrhss-1518	63	17	since	since	SCONJ
ajrhss-1518	63	18	the	the	DET
ajrhss-1518	63	19	study	study	NOUN
ajrhss-1518	63	20	showed	show	VERB
ajrhss-1518	63	21	a	a	DET
ajrhss-1518	63	22	decrease	decrease	NOUN
ajrhss-1518	63	23	in	in	ADP
ajrhss-1518	63	24	the	the	DET
ajrhss-1518	63	25	duration	duration	NOUN
ajrhss-1518	63	26	of	of	ADP
ajrhss-1518	63	27	the	the	DET
ajrhss-1518	63	28	disease	disease	NOUN
ajrhss-1518	63	29	when	when	SCONJ
ajrhss-1518	63	30	using	use	VERB
ajrhss-1518	63	31	the	the	DET
ajrhss-1518	63	32	drug	drug	NOUN
ajrhss-1518	63	33	riamilovir	riamilovir	PRON
ajrhss-1518	63	34	,	,	PUNCT
ajrhss-1518	63	35	100	100	NUM
ajrhss-1518	63	36	mg	mg	ADJ
ajrhss-1518	63	37	capsules	capsule	NOUN
ajrhss-1518	63	38	,	,	PUNCT
ajrhss-1518	63	39	compared	compare	VERB
ajrhss-1518	63	40	to	to	ADP
ajrhss-1518	63	41	placebo	placebo	NOUN
ajrhss-1518	63	42	by	by	ADP
ajrhss-1518	63	43	at	at	ADV
ajrhss-1518	63	44	least	least	ADV
ajrhss-1518	63	45	2	2	NUM
ajrhss-1518	63	46	days	day	NOUN
ajrhss-1518	63	47	.	.	PUNCT
ajrhss-1518	64	1	conclusion	conclusion	NOUN
ajrhss-1518	64	2	as	as	ADP
ajrhss-1518	64	3	a	a	DET
ajrhss-1518	64	4	result	result	NOUN
ajrhss-1518	64	5	of	of	ADP
ajrhss-1518	64	6	a	a	DET
ajrhss-1518	64	7	clinical	clinical	ADJ
ajrhss-1518	64	8	study	study	NOUN
ajrhss-1518	64	9	,	,	PUNCT
ajrhss-1518	64	10	the	the	DET
ajrhss-1518	64	11	drug	drug	NOUN
ajrhss-1518	64	12	riamilovir	riamilovir	PRON
ajrhss-1518	64	13	was	be	AUX
ajrhss-1518	64	14	found	find	VERB
ajrhss-1518	64	15	to	to	PART
ajrhss-1518	64	16	be	be	AUX
ajrhss-1518	64	17	highly	highly	ADV
ajrhss-1518	64	18	effective	effective	ADJ
ajrhss-1518	64	19	in	in	ADP
ajrhss-1518	64	20	treating	treat	VERB
ajrhss-1518	64	21	children	child	NOUN
ajrhss-1518	64	22	aged	aged	ADJ
ajrhss-1518	64	23	12–17	12–17	NUM
ajrhss-1518	64	24	years	year	NOUN
ajrhss-1518	64	25	diagnosed	diagnose	VERB
ajrhss-1518	64	26	with	with	ADP
ajrhss-1518	64	27	arvi	arvi	NOUN
ajrhss-1518	64	28	.	.	PUNCT
ajrhss-1518	65	1	in	in	ADP
ajrhss-1518	65	2	addition	addition	NOUN
ajrhss-1518	65	3	,	,	PUNCT
ajrhss-1518	65	4	the	the	DET
ajrhss-1518	65	5	safety	safety	NOUN
ajrhss-1518	65	6	and	and	CCONJ
ajrhss-1518	65	7	good	good	ADJ
ajrhss-1518	65	8	tolerability	tolerability	NOUN
ajrhss-1518	65	9	of	of	ADP
ajrhss-1518	65	10	the	the	DET
ajrhss-1518	65	11	drug	drug	NOUN
ajrhss-1518	65	12	riamilovir	riamilovir	PRON
ajrhss-1518	65	13	have	have	AUX
ajrhss-1518	65	14	been	be	AUX
ajrhss-1518	65	15	established	establish	VERB
ajrhss-1518	65	16	.	.	PUNCT
ajrhss-1518	66	1	thus	thus	ADV
ajrhss-1518	66	2	,	,	PUNCT
ajrhss-1518	66	3	we	we	PRON
ajrhss-1518	66	4	can	can	AUX
ajrhss-1518	66	5	recommend	recommend	VERB
ajrhss-1518	66	6	the	the	DET
ajrhss-1518	66	7	practical	practical	ADJ
ajrhss-1518	66	8	use	use	NOUN
ajrhss-1518	66	9	of	of	ADP
ajrhss-1518	66	10	the	the	DET
ajrhss-1518	66	11	etiotropic	etiotropic	NOUN
ajrhss-1518	66	12	antiviral	antiviral	PROPN
ajrhss-1518	66	13	drug	drug	PROPN
ajrhss-1518	66	14	riamilovir	riamilovir	PRON
ajrhss-1518	66	15	in	in	ADP
ajrhss-1518	66	16	the	the	DET
ajrhss-1518	66	17	treatment	treatment	NOUN
ajrhss-1518	66	18	of	of	ADP
ajrhss-1518	66	19	children	child	NOUN
ajrhss-1518	66	20	aged	aged	ADJ
ajrhss-1518	66	21	12–17	12–17	NUM
ajrhss-1518	66	22	years	year	NOUN
ajrhss-1518	66	23	diagnosed	diagnose	VERB
ajrhss-1518	66	24	with	with	ADP
ajrhss-1518	66	25	arvi	arvi	NOUN
ajrhss-1518	66	26	due	due	ADP
ajrhss-1518	66	27	to	to	ADP
ajrhss-1518	66	28	its	its	PRON
ajrhss-1518	66	29	high	high	ADJ
ajrhss-1518	66	30	efficiency	efficiency	NOUN
ajrhss-1518	66	31	and	and	CCONJ
ajrhss-1518	66	32	safety	safety	NOUN
ajrhss-1518	66	33	.	.	PUNCT
ajrhss-1518	67	1	the	the	DET
ajrhss-1518	67	2	introduction	introduction	NOUN
ajrhss-1518	67	3	of	of	ADP
ajrhss-1518	67	4	the	the	DET
ajrhss-1518	67	5	drug	drug	NOUN
ajrhss-1518	67	6	riamilovir	riamilovir	PRON
ajrhss-1518	67	7	into	into	ADP
ajrhss-1518	67	8	pediatric	pediatric	ADJ
ajrhss-1518	67	9	practice	practice	NOUN
ajrhss-1518	67	10	will	will	AUX
ajrhss-1518	67	11	significantly	significantly	ADV
ajrhss-1518	67	12	expand	expand	VERB
ajrhss-1518	67	13	the	the	DET
ajrhss-1518	67	14	arsenal	arsenal	NOUN
ajrhss-1518	67	15	of	of	ADP
ajrhss-1518	67	16	effective	effective	ADJ
ajrhss-1518	67	17	etiotropic	etiotropic	NOUN
ajrhss-1518	67	18	antiviral	antiviral	ADJ
ajrhss-1518	67	19	drugs	drug	NOUN
ajrhss-1518	67	20	.	.	PUNCT
ajrhss-1518	68	1	in	in	ADP
ajrhss-1518	68	2	addition	addition	NOUN
ajrhss-1518	68	3	,	,	PUNCT
ajrhss-1518	68	4	the	the	DET
ajrhss-1518	68	5	results	result	NOUN
ajrhss-1518	68	6	obtained	obtain	VERB
ajrhss-1518	68	7	allow	allow	VERB
ajrhss-1518	68	8	us	we	PRON
ajrhss-1518	68	9	to	to	PART
ajrhss-1518	68	10	recommend	recommend	VERB
ajrhss-1518	68	11	conducting	conduct	VERB
ajrhss-1518	68	12	clinical	clinical	ADJ
ajrhss-1518	68	13	studies	study	NOUN
ajrhss-1518	68	14	in	in	ADP
ajrhss-1518	68	15	a	a	DET
ajrhss-1518	68	16	younger	young	ADJ
ajrhss-1518	68	17	audience	audience	NOUN
ajrhss-1518	68	18	of	of	ADP
ajrhss-1518	68	19	patients	patient	NOUN
ajrhss-1518	68	20	(	(	PUNCT
ajrhss-1518	68	21	6–11	6–11	NOUN
ajrhss-1518	68	22	years	year	NOUN
ajrhss-1518	68	23	old	old	ADJ
ajrhss-1518	68	24	)	)	PUNCT
ajrhss-1518	68	25	diagnosed	diagnose	VERB
ajrhss-1518	68	26	with	with	ADP
ajrhss-1518	68	27	arvi	arvi	NOUN
ajrhss-1518	68	28	.	.	PUNCT
ajrhss-1518	69	1	references	reference	NOUN
ajrhss-1518	69	2	1	1	NUM
ajrhss-1518	69	3	.	.	PUNCT
ajrhss-1518	70	1	острая	острая	NOUN
ajrhss-1518	70	2	респираторная	респираторная	ADJ
ajrhss-1518	70	3	вирусная	вирусная	ADJ
ajrhss-1518	70	4	инфекция	инфекция	NOUN
ajrhss-1518	70	5	(	(	PUNCT
ajrhss-1518	70	6	орви	орви	PROPN
ajrhss-1518	70	7	)	)	PUNCT
ajrhss-1518	70	8	.	.	PUNCT
ajrhss-1518	71	1	федеральные	федеральные	NOUN
ajrhss-1518	71	2	клинические	клинические	PROPN
ajrhss-1518	71	3	рекомендации	рекомендации	VERB
ajrhss-1518	71	4	министерства	министерства	NOUN
ajrhss-1518	71	5	здравоохранения	здравоохранения	ADJ
ajrhss-1518	71	6	россии	россии	PRON
ajrhss-1518	71	7	.	.	PUNCT
ajrhss-1518	72	1	м	м	X
ajrhss-1518	72	2	.	.	PROPN
ajrhss-1518	72	3	,	,	PUNCT
ajrhss-1518	72	4	2022	2022	NUM
ajrhss-1518	72	5	.	.	PUNCT
ajrhss-1518	73	1	режим	режим	NOUN
ajrhss-1518	73	2	доступа	доступа	VERB
ajrhss-1518	73	3	:	:	PUNCT
ajrhss-1518	73	4	https://cr.minzdrav.gov.ru/recomend/25_2	https://cr.minzdrav.gov.ru/recomend/25_2	ADJ
ajrhss-1518	73	5	.	.	X
ajrhss-1518	73	6	ссылка	ссылка	PROPN
ajrhss-1518	73	7	активна	активна	PROPN
ajrhss-1518	73	8	на	на	X
ajrhss-1518	73	9	05.11.2022	05.11.2022	PRON
ajrhss-1518	74	1	[	[	X
ajrhss-1518	74	2	ostraia	ostraia	ADJ
ajrhss-1518	74	3	respiratornaia	respiratornaia	PROPN
ajrhss-1518	74	4	virusnaia	virusnaia	PROPN
ajrhss-1518	74	5	infektsiia	infektsiia	NOUN
ajrhss-1518	74	6	(	(	PUNCT
ajrhss-1518	74	7	orvi	orvi	VERB
ajrhss-1518	74	8	)	)	PUNCT
ajrhss-1518	74	9	.	.	PUNCT
ajrhss-1518	75	1	federal'nye	federal'nye	PROPN
ajrhss-1518	75	2	klinicheskie	klinicheskie	PROPN
ajrhss-1518	75	3	rekomendatsii	rekomendatsii	PROPN
ajrhss-1518	75	4	ministerstva	ministerstva	PROPN
ajrhss-1518	75	5	https://cr.minzdrav.gov.ru/recomend/25_2	https://cr.minzdrav.gov.ru/recomend/25_2	ADJ
ajrhss-1518	75	6	american	american	ADJ
ajrhss-1518	75	7	journal	journal	NOUN
ajrhss-1518	75	8	of	of	ADP
ajrhss-1518	75	9	research	research	NOUN
ajrhss-1518	75	10	in	in	ADP
ajrhss-1518	75	11	humanities	humanity	NOUN
ajrhss-1518	75	12	and	and	CCONJ
ajrhss-1518	75	13	social	social	ADJ
ajrhss-1518	75	14	sciences	science	NOUN
ajrhss-1518	75	15	volume	volume	NOUN
ajrhss-1518	75	16	18	18	NUM
ajrhss-1518	75	17	nov	nov	PROPN
ajrhss-1518	75	18	.	.	PROPN
ajrhss-1518	75	19	,	,	PUNCT
ajrhss-1518	75	20	2023	2023	NUM
ajrhss-1518	75	21	p	p	NOUN
ajrhss-1518	75	22	a	a	DET
ajrhss-1518	75	23	g	g	NOUN
ajrhss-1518	75	24	e	e	NOUN
ajrhss-1518	75	25	|	|	ADV
ajrhss-1518	75	26	140	140	NUM
ajrhss-1518	75	27	www.americanjournal.org	www.americanjournal.org	NOUN
ajrhss-1518	75	28	zdravookhraneniia	zdravookhraneniia	NOUN
ajrhss-1518	75	29	rossii	rossii	NOUN
ajrhss-1518	75	30	.	.	PUNCT
ajrhss-1518	76	1	moscow	moscow	PROPN
ajrhss-1518	76	2	,	,	PUNCT
ajrhss-1518	76	3	2022	2022	NUM
ajrhss-1518	76	4	.	.	PUNCT
ajrhss-1518	76	5	available	available	ADJ
ajrhss-1518	76	6	at	at	ADP
ajrhss-1518	76	7	:	:	PUNCT
ajrhss-1518	76	8	https://cr.minzdrav.gov.ru/recomend/25_2	https://cr.minzdrav.gov.ru/recomend/25_2	ADJ
ajrhss-1518	76	9	.	.	VERB
ajrhss-1518	76	10	accessed	access	VERB
ajrhss-1518	76	11	:	:	PUNCT
ajrhss-1518	76	12	05.11.2022	05.11.2022	X
ajrhss-1518	76	13	(	(	PUNCT
ajrhss-1518	76	14	in	in	ADP
ajrhss-1518	76	15	russian	russian	NOUN
ajrhss-1518	76	16	)	)	PUNCT
ajrhss-1518	76	17	]	]	PUNCT
ajrhss-1518	76	18	.	.	PUNCT
ajrhss-1518	77	1	2	2	X
ajrhss-1518	77	2	.	.	X
ajrhss-1518	77	3	muxtorova	muxtorova	PROPN
ajrhss-1518	77	4	,	,	PUNCT
ajrhss-1518	77	5	s.	s.	PROPN
ajrhss-1518	77	6	a.	a.	PROPN
ajrhss-1518	77	7	(	(	PUNCT
ajrhss-1518	77	8	2022	2022	NUM
ajrhss-1518	77	9	)	)	PUNCT
ajrhss-1518	77	10	.	.	PUNCT
ajrhss-1518	78	1	clinical	clinical	ADJ
ajrhss-1518	78	2	and	and	CCONJ
ajrhss-1518	78	3	laboratoriya	laboratoriya	NOUN
ajrhss-1518	78	4	features	feature	NOUN
ajrhss-1518	78	5	of	of	ADP
ajrhss-1518	78	6	acute	acute	ADJ
ajrhss-1518	78	7	respiratory	respiratory	ADJ
ajrhss-1518	78	8	disease	disease	NOUN
ajrhss-1518	78	9	in	in	ADP
ajrhss-1518	78	10	frequently	frequently	ADV
ajrhss-1518	78	11	ill	ill	ADJ
ajrhss-1518	78	12	children	child	NOUN
ajrhss-1518	78	13	.	.	PUNCT
ajrhss-1518	79	1	web	web	NOUN
ajrhss-1518	79	2	of	of	ADP
ajrhss-1518	79	3	scientist	scientist	NOUN
ajrhss-1518	79	4	:	:	PUNCT
ajrhss-1518	79	5	international	international	ADJ
ajrhss-1518	79	6	scientific	scientific	ADJ
ajrhss-1518	79	7	research	research	NOUN
ajrhss-1518	79	8	journal	journal	NOUN
ajrhss-1518	79	9	,	,	PUNCT
ajrhss-1518	79	10	1026	1026	NUM
ajrhss-1518	79	11	-	-	SYM
ajrhss-1518	79	12	1030	1030	NUM
ajrhss-1518	79	13	.	.	PUNCT
ajrhss-1518	80	1	3	3	X
ajrhss-1518	80	2	.	.	X
ajrhss-1518	80	3	о	о	PROPN
ajrhss-1518	80	4	заболеваемости	заболеваемости	PROPN
ajrhss-1518	80	5	гриппом	гриппом	PROPN
ajrhss-1518	80	6	и	и	PROPN
ajrhss-1518	80	7	орви	орви	PROPN
ajrhss-1518	80	8	.	.	PUNCT
ajrhss-1518	81	1	режим	режим	NOUN
ajrhss-1518	81	2	доступа	доступа	VERB
ajrhss-1518	81	3	:	:	PUNCT
ajrhss-1518	82	1	http://36.rospotrebnadzor.ru/keyareas/prevention-infectious-diseases/statistics/15357	http://36.rospotrebnadzor.ru/keyareas/prevention-infectious-diseases/statistics/15357	PROPN
ajrhss-1518	82	2	.	.	PUNCT
ajrhss-1518	83	1	ссылка	ссылка	PROPN
ajrhss-1518	83	2	активна	активна	PROPN
ajrhss-1518	83	3	на	на	PROPN
ajrhss-1518	83	4	18.11.2022	18.11.2022	NUM
ajrhss-1518	84	1	[	[	X
ajrhss-1518	84	2	o	o	X
ajrhss-1518	84	3	zabolevaemosti	zabolevaemosti	X
ajrhss-1518	84	4	grippom	grippom	NOUN
ajrhss-1518	84	5	i	i	PRON
ajrhss-1518	84	6	orvi	orvi	VERB
ajrhss-1518	84	7	.	.	PUNCT
ajrhss-1518	84	8	available	available	ADJ
ajrhss-1518	84	9	at	at	ADP
ajrhss-1518	84	10	:	:	PUNCT
ajrhss-1518	84	11	http://36.rospotrebnadzor.ru/key-areas/preventioninfectious-diseases/statistics/15357	http://36.rospotrebnadzor.ru/key-areas/preventioninfectious-diseases/statistics/15357	PROPN
ajrhss-1518	84	12	.	.	PUNCT
ajrhss-1518	85	1	accessed	access	VERB
ajrhss-1518	85	2	:	:	PUNCT
ajrhss-1518	85	3	18.11.2022	18.11.2022	NUM
ajrhss-1518	85	4	(	(	PUNCT
ajrhss-1518	85	5	in	in	ADP
ajrhss-1518	85	6	russian	russian	NOUN
ajrhss-1518	85	7	)	)	PUNCT
ajrhss-1518	85	8	]	]	PUNCT
ajrhss-1518	85	9	.	.	PUNCT
ajrhss-1518	86	1	4	4	X
ajrhss-1518	86	2	.	.	X
ajrhss-1518	86	3	mukhtarova	mukhtarova	PROPN
ajrhss-1518	86	4	,	,	PUNCT
ajrhss-1518	86	5	s.	s.	PROPN
ajrhss-1518	86	6	h.	h.	PROPN
ajrhss-1518	86	7	(	(	PUNCT
ajrhss-1518	86	8	2022	2022	NUM
ajrhss-1518	86	9	)	)	PUNCT
ajrhss-1518	86	10	.	.	PUNCT
ajrhss-1518	87	1	a.(2022	a.(2022	NOUN
ajrhss-1518	87	2	)	)	PUNCT
ajrhss-1518	87	3	age	age	NOUN
ajrhss-1518	87	4	-	-	PUNCT
ajrhss-1518	87	5	related	relate	VERB
ajrhss-1518	87	6	features	feature	NOUN
ajrhss-1518	87	7	of	of	ADP
ajrhss-1518	87	8	clinical	clinical	ADJ
ajrhss-1518	87	9	manifestations	manifestation	NOUN
ajrhss-1518	87	10	of	of	ADP
ajrhss-1518	87	11	giardiasis	giardiasis	NOUN
ajrhss-1518	87	12	.	.	PUNCT
ajrhss-1518	88	1	international	international	ADJ
ajrhss-1518	88	2	journal	journal	PROPN
ajrhss-1518	88	3	of	of	ADP
ajrhss-1518	88	4	medical	medical	ADJ
ajrhss-1518	88	5	sciences	science	NOUN
ajrhss-1518	88	6	and	and	CCONJ
ajrhss-1518	88	7	clinical	clinical	ADJ
ajrhss-1518	88	8	research	research	NOUN
ajrhss-1518	88	9	,	,	PUNCT
ajrhss-1518	88	10	17	17	NUM
ajrhss-1518	88	11	-	-	SYM
ajrhss-1518	88	12	21	21	NUM
ajrhss-1518	88	13	.	.	PUNCT
ajrhss-1518	89	1	5	5	NUM
ajrhss-1518	89	2	.	.	X
ajrhss-1518	89	3	williams	williams	PROPN
ajrhss-1518	89	4	bg	bg	PROPN
ajrhss-1518	89	5	,	,	PUNCT
ajrhss-1518	89	6	gouws	gouw	VERB
ajrhss-1518	89	7	e	e	NOUN
ajrhss-1518	89	8	,	,	PUNCT
ajrhss-1518	89	9	boschi	boschi	NOUN
ajrhss-1518	89	10	-	-	NOUN
ajrhss-1518	89	11	pinto	pinto	NOUN
ajrhss-1518	89	12	c	c	NOUN
ajrhss-1518	89	13	,	,	PUNCT
ajrhss-1518	89	14	et	et	PROPN
ajrhss-1518	89	15	al	al	PROPN
ajrhss-1518	89	16	.	.	PROPN
ajrhss-1518	89	17	estimates	estimate	NOUN
ajrhss-1518	89	18	of	of	ADP
ajrhss-1518	89	19	world	world	NOUN
ajrhss-1518	89	20	-	-	PUNCT
ajrhss-1518	89	21	wide	wide	ADJ
ajrhss-1518	89	22	distribution	distribution	NOUN
ajrhss-1518	89	23	of	of	ADP
ajrhss-1518	89	24	child	child	NOUN
ajrhss-1518	89	25	deaths	death	NOUN
ajrhss-1518	89	26	from	from	ADP
ajrhss-1518	89	27	acute	acute	ADJ
ajrhss-1518	89	28	respiratory	respiratory	ADJ
ajrhss-1518	89	29	infections	infection	NOUN
ajrhss-1518	89	30	.	.	PUNCT
ajrhss-1518	90	1	lancet	lancet	PROPN
ajrhss-1518	90	2	infect	infect	PROPN
ajrhss-1518	90	3	dis	dis	PROPN
ajrhss-1518	90	4	.	.	PUNCT
ajrhss-1518	91	1	2002;2(1):25	2002;2(1):25	NUM
ajrhss-1518	91	2	-	-	SYM
ajrhss-1518	91	3	32	32	NUM
ajrhss-1518	91	4	.	.	PUNCT
ajrhss-1518	92	1	doi	doi	NOUN
ajrhss-1518	92	2	:	:	PUNCT
ajrhss-1518	92	3	10.1016	10.1016	NUM
ajrhss-1518	92	4	/	/	SYM
ajrhss-1518	92	5	s14733099(01)00170	s14733099(01)00170	NOUN
ajrhss-1518	92	6	-	-	PUNCT
ajrhss-1518	92	7	0	0	NUM
ajrhss-1518	92	8	6	6	NUM
ajrhss-1518	92	9	.	.	PUNCT
ajrhss-1518	93	1	avendaño	avendaño	PROPN
ajrhss-1518	93	2	carvajal	carvajal	PROPN
ajrhss-1518	93	3	l	l	PROPN
ajrhss-1518	93	4	,	,	PUNCT
ajrhss-1518	93	5	perret	perret	PROPN
ajrhss-1518	93	6	pérez	pérez	PROPN
ajrhss-1518	93	7	c.	c.	PROPN
ajrhss-1518	93	8	epidemiology	epidemiology	NOUN
ajrhss-1518	93	9	of	of	ADP
ajrhss-1518	93	10	respiratory	respiratory	ADJ
ajrhss-1518	93	11	infections	infection	NOUN
ajrhss-1518	93	12	.	.	PUNCT
ajrhss-1518	94	1	pediatric	pediatric	ADJ
ajrhss-1518	94	2	respiratory	respiratory	ADJ
ajrhss-1518	94	3	diseases	disease	NOUN
ajrhss-1518	94	4	.	.	PUNCT
ajrhss-1518	95	1	cham	cham	PROPN
ajrhss-1518	95	2	:	:	PUNCT
ajrhss-1518	95	3	springer	springer	NOUN
ajrhss-1518	95	4	international	international	ADJ
ajrhss-1518	95	5	publishing	publishing	NOUN
ajrhss-1518	95	6	,	,	PUNCT
ajrhss-1518	95	7	2020	2020	NUM
ajrhss-1518	95	8	.	.	PUNCT
ajrhss-1518	96	1	doi	doi	NOUN
ajrhss-1518	96	2	:	:	PUNCT
ajrhss-1518	96	3	10.1007/978	10.1007/978	NUM
ajrhss-1518	96	4	-	-	SYM
ajrhss-1518	96	5	3	3	NUM
ajrhss-1518	96	6	-	-	PUNCT
ajrhss-1518	96	7	03026961	03026961	NUM
ajrhss-1518	96	8	-	-	PUNCT
ajrhss-1518	96	9	6_28	6_28	NUM
ajrhss-1518	96	10	7	7	NUM
ajrhss-1518	96	11	.	.	PUNCT
ajrhss-1518	96	12	ma	ma	PROPN
ajrhss-1518	96	13	x	x	PROPN
ajrhss-1518	96	14	,	,	PUNCT
ajrhss-1518	96	15	conrad	conrad	PROPN
ajrhss-1518	96	16	t	t	PROPN
ajrhss-1518	96	17	,	,	PUNCT
ajrhss-1518	96	18	alchikh	alchikh	PROPN
ajrhss-1518	96	19	m	m	PROPN
ajrhss-1518	96	20	,	,	PUNCT
ajrhss-1518	96	21	et	et	PROPN
ajrhss-1518	96	22	al	al	PROPN
ajrhss-1518	96	23	.	.	PUNCT
ajrhss-1518	97	1	can	can	AUX
ajrhss-1518	97	2	we	we	PRON
ajrhss-1518	97	3	distinguish	distinguish	VERB
ajrhss-1518	97	4	respiratory	respiratory	ADJ
ajrhss-1518	97	5	viral	viral	ADJ
ajrhss-1518	97	6	infections	infection	NOUN
ajrhss-1518	97	7	based	base	VERB
ajrhss-1518	97	8	on	on	ADP
ajrhss-1518	97	9	clinical	clinical	ADJ
ajrhss-1518	97	10	features	feature	NOUN
ajrhss-1518	97	11	?	?	PUNCT
ajrhss-1518	98	1	a	a	DET
ajrhss-1518	98	2	prospective	prospective	ADJ
ajrhss-1518	98	3	pediatric	pediatric	ADJ
ajrhss-1518	98	4	cohort	cohort	NOUN
ajrhss-1518	98	5	compared	compare	VERB
ajrhss-1518	98	6	to	to	ADP
ajrhss-1518	98	7	systematic	systematic	ADJ
ajrhss-1518	98	8	literature	literature	PROPN
ajrhss-1518	98	9	review	review	PROPN
ajrhss-1518	98	10	.	.	PUNCT
ajrhss-1518	99	1	rev	rev	PROPN
ajrhss-1518	99	2	med	med	PROPN
ajrhss-1518	99	3	virol	virol	NOUN
ajrhss-1518	99	4	.	.	PUNCT
ajrhss-1518	100	1	2018;28	2018;28	NOUN
ajrhss-1518	100	2	:	:	PUNCT
ajrhss-1518	100	3	e1997	e1997	NOUN
ajrhss-1518	100	4	.	.	NOUN
ajrhss-1518	100	5	8	8	NUM
ajrhss-1518	100	6	.	.	X
ajrhss-1518	100	7	mukhtorova	mukhtorova	PROPN
ajrhss-1518	101	1	shokhida	shokhida	PROPN
ajrhss-1518	101	2	abdulloevna	abdulloevna	VERB
ajrhss-1518	101	3	.	.	PUNCT
ajrhss-1518	102	1	(	(	PUNCT
ajrhss-1518	102	2	2023	2023	NUM
ajrhss-1518	102	3	)	)	PUNCT
ajrhss-1518	102	4	.	.	PUNCT
ajrhss-1518	103	1	microbiological	microbiological	ADJ
ajrhss-1518	103	2	indicators	indicator	NOUN
ajrhss-1518	103	3	of	of	ADP
ajrhss-1518	103	4	patients	patient	NOUN
ajrhss-1518	103	5	infected	infect	VERB
ajrhss-1518	103	6	with	with	ADP
ajrhss-1518	103	7	sarscov-2	sarscov-2	PROPN
ajrhss-1518	103	8	.	.	PUNCT
ajrhss-1518	104	1	texas	texas	PROPN
ajrhss-1518	104	2	journal	journal	PROPN
ajrhss-1518	104	3	of	of	ADP
ajrhss-1518	104	4	medical	medical	ADJ
ajrhss-1518	104	5	science	science	NOUN
ajrhss-1518	104	6	,	,	PUNCT
ajrhss-1518	104	7	21	21	NUM
ajrhss-1518	104	8	,	,	PUNCT
ajrhss-1518	104	9	41–45	41–45	NUM
ajrhss-1518	104	10	.	.	PUNCT
ajrhss-1518	104	11	retrieved	retrieve	VERB
ajrhss-1518	104	12	from	from	ADP
ajrhss-1518	104	13	https://www.zienjournals.com/index.php/tjms/article/view/4116	https://www.zienjournals.com/index.php/tjms/article/view/4116	PROPN
ajrhss-1518	104	14	9	9	NUM
ajrhss-1518	104	15	.	.	PUNCT
ajrhss-1518	105	1	ilechukwu	ilechukwu	PROPN
ajrhss-1518	105	2	gc	gc	PROPN
ajrhss-1518	105	3	,	,	PUNCT
ajrhss-1518	105	4	ilechukwu	ilechukwu	PROPN
ajrhss-1518	105	5	cga	cga	PROPN
ajrhss-1518	105	6	,	,	PUNCT
ajrhss-1518	105	7	ubesie	ubesie	NOUN
ajrhss-1518	105	8	ac	ac	PROPN
ajrhss-1518	105	9	,	,	PUNCT
ajrhss-1518	105	10	et	et	PROPN
ajrhss-1518	105	11	al	al	PROPN
ajrhss-1518	105	12	.	.	PUNCT
ajrhss-1518	106	1	otitis	otitis	NOUN
ajrhss-1518	106	2	media	medium	NOUN
ajrhss-1518	106	3	in	in	ADP
ajrhss-1518	106	4	children	child	NOUN
ajrhss-1518	106	5	:	:	PUNCT
ajrhss-1518	106	6	review	review	NOUN
ajrhss-1518	106	7	article	article	NOUN
ajrhss-1518	106	8	.	.	PUNCT
ajrhss-1518	107	1	open	open	ADJ
ajrhss-1518	107	2	j	j	PROPN
ajrhss-1518	107	3	pediatr	pediatr	NOUN
ajrhss-1518	107	4	.	.	PUNCT
ajrhss-1518	108	1	2014;04(01):47	2014;04(01):47	NUM
ajrhss-1518	108	2	-	-	SYM
ajrhss-1518	108	3	53	53	NUM
ajrhss-1518	108	4	.	.	PUNCT
ajrhss-1518	109	1	doi	doi	NOUN
ajrhss-1518	109	2	:	:	PUNCT
ajrhss-1518	109	3	10.4236	10.4236	NUM
ajrhss-1518	109	4	/	/	SYM
ajrhss-1518	109	5	ojped.2014.41006	ojped.2014.41006	NUM
ajrhss-1518	109	6	10	10	NUM
ajrhss-1518	109	7	.	.	PUNCT
ajrhss-1518	110	1	oblokulov	oblokulov	PROPN
ajrhss-1518	110	2	abdurashid	abdurashid	PROPN
ajrhss-1518	110	3	rakhimovich	rakhimovich	PROPN
ajrhss-1518	110	4	mukhammadieva	mukhammadieva	PROPN
ajrhss-1518	110	5	musharraf	musharraf	PROPN
ajrhss-1518	110	6	ibrokhimovna	ibrokhimovna	PROPN
ajrhss-1518	110	7	sanokulova	sanokulova	PROPN
ajrhss-1518	110	8	sitora	sitora	PROPN
ajrhss-1518	110	9	avazovna	avazovna	PROPN
ajrhss-1518	110	10	khadieva	khadieva	PROPN
ajrhss-1518	110	11	dora	dora	PROPN
ajrhss-1518	110	12	isakovna	isakovna	PROPN
ajrhss-1518	110	13	.	.	PUNCT
ajrhss-1518	111	1	(	(	PUNCT
ajrhss-1518	111	2	2023	2023	NUM
ajrhss-1518	111	3	)	)	PUNCT
ajrhss-1518	111	4	.	.	PUNCT
ajrhss-1518	112	1	clinical	clinical	ADJ
ajrhss-1518	112	2	and	and	CCONJ
ajrhss-1518	112	3	laboratory	laboratory	NOUN
ajrhss-1518	112	4	features	feature	NOUN
ajrhss-1518	112	5	of	of	ADP
ajrhss-1518	112	6	spontaneous	spontaneous	ADJ
ajrhss-1518	112	7	bacterial	bacterial	ADJ
ajrhss-1518	112	8	peritonitis	peritonitis	NOUN
ajrhss-1518	112	9	in	in	ADP
ajrhss-1518	112	10	patients	patient	NOUN
ajrhss-1518	112	11	with	with	ADP
ajrhss-1518	112	12	viral	viral	ADJ
ajrhss-1518	112	13	liver	liver	NOUN
ajrhss-1518	112	14	cirrhosis	cirrhosis	NOUN
ajrhss-1518	112	15	.	.	PUNCT
ajrhss-1518	113	1	journal	journal	NOUN
ajrhss-1518	113	2	of	of	ADP
ajrhss-1518	113	3	advanced	advanced	ADJ
ajrhss-1518	113	4	zoology	zoology	NOUN
ajrhss-1518	113	5	,	,	PUNCT
ajrhss-1518	113	6	44(s-2	44(s-2	NUM
ajrhss-1518	113	7	)	)	PUNCT
ajrhss-1518	113	8	,	,	PUNCT
ajrhss-1518	113	9	3744–3750	3744–3750	NUM
ajrhss-1518	113	10	.	.	PUNCT
ajrhss-1518	113	11	retrieved	retrieve	VERB
ajrhss-1518	113	12	from	from	ADP
ajrhss-1518	113	13	http://jazindia.com/index.php/jaz/article/view/1716	http://jazindia.com/index.php/jaz/article/view/1716	NOUN
ajrhss-1518	113	14	11	11	NUM
ajrhss-1518	113	15	.	.	PUNCT
ajrhss-1518	114	1	mухаммадиевa	mухаммадиевa	PROPN
ajrhss-1518	114	2	m.и	m.и	PROPN
ajrhss-1518	114	3	.	.	PROPN
ajrhss-1518	114	4	(	(	PUNCT
ajrhss-1518	114	5	2023	2023	NUM
ajrhss-1518	114	6	)	)	PUNCT
ajrhss-1518	114	7	.	.	PUNCT
ajrhss-1518	115	1	bирус	bирус	PROPN
ajrhss-1518	115	2	этиологияли	этиологияли	NOUN
ajrhss-1518	115	3	жигар	жигар	NOUN
ajrhss-1518	115	4	циррози	циррози	NOUN
ajrhss-1518	115	5	беморларида	беморларида	NOUN
ajrhss-1518	115	6	спонтан	спонтан	NOUN
ajrhss-1518	115	7	бактериал	бактериал	ADJ
ajrhss-1518	115	8	перитонит	перитонит	NOUN
ajrhss-1518	115	9	билан	билан	ADV
ajrhss-1518	115	10	асоратланишнинг	асоратланишнинг	VERB
ajrhss-1518	115	11	профилактикаси	профилактикаси	NOUN
ajrhss-1518	115	12	ва	ва	NOUN
ajrhss-1518	115	13	давосини	давосини	VERB
ajrhss-1518	115	14	такомиллаштириш//oriental	такомиллаштириш//oriental	ADJ
ajrhss-1518	115	15	renaissance	renaissance	NOUN
ajrhss-1518	115	16	:	:	PUNCT
ajrhss-1518	115	17	innovative	innovative	ADJ
ajrhss-1518	115	18	,	,	PUNCT
ajrhss-1518	115	19	educational	educational	ADJ
ajrhss-1518	115	20	,	,	PUNCT
ajrhss-1518	115	21	natural	natural	ADJ
ajrhss-1518	115	22	and	and	CCONJ
ajrhss-1518	115	23	social	social	ADJ
ajrhss-1518	115	24	sciences	science	NOUN
ajrhss-1518	115	25	.	.	PUNCT
ajrhss-1518	116	1	2023.-p.947	2023.-p.947	NUM
ajrhss-1518	116	2	-	-	SYM
ajrhss-1518	116	3	953	953	NUM
ajrhss-1518	116	4	.	.	PUNCT
ajrhss-1518	117	1	12	12	NUM
ajrhss-1518	117	2	.	.	PUNCT
ajrhss-1518	118	1	sanokulova	sanokulova	PROPN
ajrhss-1518	118	2	s.a	s.a	PROPN
ajrhss-1518	118	3	(	(	PUNCT
ajrhss-1518	118	4	2023	2023	NUM
ajrhss-1518	118	5	)	)	PUNCT
ajrhss-1518	118	6	clinical	clinical	ADJ
ajrhss-1518	118	7	and	and	CCONJ
ajrhss-1518	118	8	important	important	ADJ
ajrhss-1518	118	9	diagnostic	diagnostic	ADJ
ajrhss-1518	118	10	features	feature	NOUN
ajrhss-1518	118	11	in	in	ADP
ajrhss-1518	118	12	the	the	DET
ajrhss-1518	118	13	combination	combination	NOUN
ajrhss-1518	118	14	of	of	ADP
ajrhss-1518	118	15	giardiasis	giardiasis	NOUN
ajrhss-1518	118	16	with	with	ADP
ajrhss-1518	118	17	helminthiasis//	helminthiasis//	PROPN
ajrhss-1518	118	18	european	european	PROPN
ajrhss-1518	118	19	journal	journal	PROPN
ajrhss-1518	118	20	of	of	ADP
ajrhss-1518	118	21	modern	modern	ADJ
ajrhss-1518	118	22	medicine	medicine	NOUN
ajrhss-1518	118	23	and	and	CCONJ
ajrhss-1518	118	24	practice	practice	NOUN
ajrhss-1518	118	25	.	.	PUNCT
ajrhss-1518	119	1	№	№	ADP
ajrhss-1518	119	2	01	01	NUM
ajrhss-1518	119	3	p-23	p-23	NOUN
ajrhss-1518	119	4	-	-	PUNCT
ajrhss-1518	119	5	26	26	NUM
ajrhss-1518	119	6	13	13	NUM
ajrhss-1518	119	7	.	.	PUNCT
ajrhss-1518	120	1	mukhtorova	mukhtorova	PROPN
ajrhss-1518	120	2	shokhida	shokhida	PROPN
ajrhss-1518	120	3	abdulloevna	abdulloevna	VERB
ajrhss-1518	120	4	.	.	PUNCT
ajrhss-1518	121	1	(	(	PUNCT
ajrhss-1518	121	2	2023	2023	NUM
ajrhss-1518	121	3	)	)	PUNCT
ajrhss-1518	121	4	.	.	PUNCT
ajrhss-1518	122	1	cytomegalovirus	cytomegalovirus	NOUN
ajrhss-1518	122	2	infections	infection	NOUN
ajrhss-1518	122	3	in	in	ADP
ajrhss-1518	122	4	children	child	NOUN
ajrhss-1518	122	5	with	with	ADP
ajrhss-1518	122	6	primary	primary	ADJ
ajrhss-1518	122	7	and	and	CCONJ
ajrhss-1518	122	8	secondary	secondary	ADJ
ajrhss-1518	122	9	immune	immune	ADJ
ajrhss-1518	122	10	deficiencies	deficiency	NOUN
ajrhss-1518	122	11	.	.	PUNCT
ajrhss-1518	123	1	academia	academia	PROPN
ajrhss-1518	123	2	science	science	PROPN
ajrhss-1518	123	3	repository	repository	NOUN
ajrhss-1518	123	4	,	,	PUNCT
ajrhss-1518	123	5	4(06	4(06	NUM
ajrhss-1518	123	6	)	)	PUNCT
ajrhss-1518	123	7	,	,	PUNCT
ajrhss-1518	123	8	23–28	23–28	NUM
ajrhss-1518	123	9	.	.	PUNCT
ajrhss-1518	123	10	retrieved	retrieve	VERB
ajrhss-1518	123	11	from	from	ADP
ajrhss-1518	123	12	http://academiascience.com/index.php/repo/article/view/832	http://academiascience.com/index.php/repo/article/view/832	PROPN
ajrhss-1518	123	13	14	14	NUM
ajrhss-1518	123	14	.	.	PUNCT
ajrhss-1518	124	1	oblokulov	oblokulov	ADJ
ajrhss-1518	124	2	.	.	PUNCT
ajrhss-1518	125	1	a.r	a.r	PROPN
ajrhss-1518	125	2	.	.	PROPN
ajrhss-1518	125	3	,	,	PUNCT
ajrhss-1518	125	4	m.i	m.i	PROPN
ajrhss-1518	125	5	.	.	PROPN
ajrhss-1518	125	6	mukhammadieva.(2022	mukhammadieva.(2022	PROPN
ajrhss-1518	125	7	)	)	PUNCT
ajrhss-1518	125	8	.	.	PUNCT
ajrhss-1518	126	1	clinical	clinical	ADJ
ajrhss-1518	126	2	and	and	CCONJ
ajrhss-1518	126	3	biochemical	biochemical	ADJ
ajrhss-1518	126	4	characteristics	characteristic	NOUN
ajrhss-1518	126	5	of	of	ADP
ajrhss-1518	126	6	liver	liver	NOUN
ajrhss-1518	126	7	cirrhosis	cirrhosis	NOUN
ajrhss-1518	126	8	patients	patient	NOUN
ajrhss-1518	126	9	of	of	ADP
ajrhss-1518	126	10	viral	viral	ADJ
ajrhss-1518	126	11	etiology	etiology	NOUN
ajrhss-1518	126	12	with	with	ADP
ajrhss-1518	126	13	spontaneous	spontaneous	ADJ
ajrhss-1518	126	14	bacterial	bacterial	ADJ
ajrhss-1518	126	15	peritonitis//academicia	peritonitis//academicia	NOUN
ajrhss-1518	126	16	globe	globe	NOUN
ajrhss-1518	126	17	:	:	PUNCT
ajrhss-1518	126	18	indersciense	indersciense	NOUN
ajrhss-1518	126	19	research.-2022.p	research.-2022.p	NUM
ajrhss-1518	126	20	.	.	PUNCT
ajrhss-1518	127	1	210	210	NUM
ajrhss-1518	127	2	-	-	SYM
ajrhss-1518	127	3	216	216	NUM
ajrhss-1518	127	4	https://cr.minzdrav.gov.ru/recomend/25_2	https://cr.minzdrav.gov.ru/recomend/25_2	NOUN
ajrhss-1518	127	5	http://36.rospotrebnadzor.ru/key-areas/prevention-infectious-diseases/statistics/15357	http://36.rospotrebnadzor.ru/key-areas/prevention-infectious-diseases/statistics/15357	NOUN
ajrhss-1518	127	6	http://36.rospotrebnadzor.ru/key-areas/prevention-infectious-diseases/statistics/15357	http://36.rospotrebnadzor.ru/key-areas/prevention-infectious-diseases/statistics/15357	NOUN
ajrhss-1518	127	7	http://36.rospotrebnadzor.ru/key-areas/prevention-infectious-diseases/statistics/15357	http://36.rospotrebnadzor.ru/key-areas/prevention-infectious-diseases/statistics/15357	NOUN
ajrhss-1518	127	8	http://36.rospotrebnadzor.ru/key-areas/prevention-infectious-diseases/statistics/15357	http://36.rospotrebnadzor.ru/key-areas/prevention-infectious-diseases/statistics/15357	NOUN
ajrhss-1518	127	9	https://doi.org/10.1016/s1473-3099(01)00170-0	https://doi.org/10.1016/s1473-3099(01)00170-0	NOUN
ajrhss-1518	127	10	https://doi.org/10.1016/s1473-3099(01)00170-0	https://doi.org/10.1016/s1473-3099(01)00170-0	NOUN
ajrhss-1518	127	11	https://doi.org/10.1007/978-3-030-26961-6_28	https://doi.org/10.1007/978-3-030-26961-6_28	PROPN
ajrhss-1518	127	12	https://doi.org/10.1007/978-3-030-26961-6_28	https://doi.org/10.1007/978-3-030-26961-6_28	PROPN
ajrhss-1518	127	13	https://www.zienjournals.com/index.php/tjms/article/view/4116	https://www.zienjournals.com/index.php/tjms/article/view/4116	CCONJ
ajrhss-1518	127	14	https://doi.org/10.4236/ojped.2014.41006	https://doi.org/10.4236/ojped.2014.41006	PROPN
ajrhss-1518	127	15	http://academiascience.com/index.php/repo/article/view/832	http://academiascience.com/index.php/repo/article/view/832	PROPN
ajrhss-1518	127	16	american	american	ADJ
ajrhss-1518	127	17	journal	journal	PROPN
ajrhss-1518	127	18	of	of	ADP
ajrhss-1518	127	19	research	research	NOUN
ajrhss-1518	127	20	in	in	ADP
ajrhss-1518	127	21	humanities	humanity	NOUN
ajrhss-1518	127	22	and	and	CCONJ
ajrhss-1518	127	23	social	social	ADJ
ajrhss-1518	127	24	sciences	science	NOUN
ajrhss-1518	127	25	volume	volume	NOUN
ajrhss-1518	127	26	18	18	NUM
ajrhss-1518	127	27	nov	nov	PROPN
ajrhss-1518	127	28	.	.	PROPN
ajrhss-1518	127	29	,	,	PUNCT
ajrhss-1518	127	30	2023	2023	NUM
ajrhss-1518	127	31	p	p	NOUN
ajrhss-1518	127	32	a	a	DET
ajrhss-1518	127	33	g	g	NOUN
ajrhss-1518	127	34	e	e	NOUN
ajrhss-1518	127	35	|	|	NOUN
ajrhss-1518	127	36	141	141	NUM
ajrhss-1518	127	37	www.americanjournal.org	www.americanjournal.org	NOUN
ajrhss-1518	127	38	15	15	NUM
ajrhss-1518	127	39	.	.	PUNCT
ajrhss-1518	128	1	aslonova.m.r	aslonova.m.r	VERB
ajrhss-1518	128	2	.	.	PUNCT
ajrhss-1518	129	1	(	(	PUNCT
ajrhss-1518	129	2	2023	2023	NUM
ajrhss-1518	129	3	)	)	PUNCT
ajrhss-1518	129	4	.	.	PUNCT
ajrhss-1518	130	1	vitamin	vitamin	NOUN
ajrhss-1518	130	2	deficiency	deficiency	NOUN
ajrhss-1518	130	3	cases	case	NOUN
ajrhss-1518	130	4	resulting	result	VERB
ajrhss-1518	130	5	from	from	ADP
ajrhss-1518	130	6	parasitic	parasitic	ADJ
ajrhss-1518	130	7	diseases	disease	NOUN
ajrhss-1518	130	8	//	//	PUNCT
ajrhss-1518	130	9	galaxy	galaxy	PROPN
ajrhss-1518	130	10	international	international	ADJ
ajrhss-1518	130	11	interdisciplinary	interdisciplinary	ADJ
ajrhss-1518	130	12	research	research	NOUN
ajrhss-1518	130	13	journal.-2023.-p	journal.-2023.-p	NOUN
ajrhss-1518	130	14	.	.	PUNCT
ajrhss-1518	131	1	404	404	NUM
ajrhss-1518	131	2	-	-	SYM
ajrhss-1518	131	3	409	409	NUM
ajrhss-1518	131	4	16	16	NUM
ajrhss-1518	131	5	.	.	PUNCT
ajrhss-1518	132	1	токин	токин	PROPN
ajrhss-1518	132	2	и.и	и.и	PROPN
ajrhss-1518	132	3	.	.	PROPN
ajrhss-1518	132	4	,	,	PUNCT
ajrhss-1518	132	5	зубкова	зубкова	VERB
ajrhss-1518	132	6	т.г	т.г	PROPN
ajrhss-1518	132	7	.	.	PROPN
ajrhss-1518	132	8	,	,	PUNCT
ajrhss-1518	132	9	дроздова	дроздова	PROPN
ajrhss-1518	132	10	ю.в	ю.в	PROPN
ajrhss-1518	132	11	.	.	PROPN
ajrhss-1518	132	12	,	,	PUNCT
ajrhss-1518	132	13	лиознов	лиознов	PROPN
ajrhss-1518	132	14	д.а	д.а	PROPN
ajrhss-1518	132	15	.	.	PROPN
ajrhss-1518	132	16	опыт	опыт	PROPN
ajrhss-1518	132	17	этиотропной	этиотропной	PROPN
ajrhss-1518	132	18	терапии	терапии	PROPN
ajrhss-1518	132	19	орви	орви	PROPN
ajrhss-1518	132	20	отечественным	отечественным	ADJ
ajrhss-1518	132	21	противовирусным	противовирусным	ADJ
ajrhss-1518	132	22	препаратом	препаратом	NOUN
ajrhss-1518	132	23	.	.	PUNCT
ajrhss-1518	133	1	инфекционные	инфекционные	ADJ
ajrhss-1518	133	2	болезни	болезни	NOUN
ajrhss-1518	133	3	.	.	PUNCT
ajrhss-1518	134	1	2019;17(4):13	2019;17(4):13	X
ajrhss-1518	134	2	-	-	SYM
ajrhss-1518	134	3	7	7	NUM
ajrhss-1518	134	4	[	[	X
ajrhss-1518	134	5	tokin	tokin	NOUN
ajrhss-1518	134	6	ii	ii	PROPN
ajrhss-1518	134	7	,	,	PUNCT
ajrhss-1518	134	8	zubkova	zubkova	PROPN
ajrhss-1518	134	9	tg	tg	PROPN
ajrhss-1518	134	10	,	,	PUNCT
ajrhss-1518	134	11	drozdova	drozdova	PROPN
ajrhss-1518	134	12	yuv	yuv	PROPN
ajrhss-1518	134	13	,	,	PUNCT
ajrhss-1518	134	14	lioznov	lioznov	PROPN
ajrhss-1518	134	15	da	da	PROPN
ajrhss-1518	134	16	.	.	PUNCT
ajrhss-1518	134	17	experience	experience	NOUN
ajrhss-1518	134	18	of	of	ADP
ajrhss-1518	134	19	etiotropic	etiotropic	NOUN
ajrhss-1518	134	20	therapy	therapy	NOUN
ajrhss-1518	134	21	of	of	ADP
ajrhss-1518	134	22	acute	acute	ADJ
ajrhss-1518	134	23	respiratory	respiratory	ADJ
ajrhss-1518	134	24	viral	viral	ADJ
ajrhss-1518	134	25	infection	infection	NOUN
ajrhss-1518	134	26	with	with	ADP
ajrhss-1518	134	27	domestic	domestic	ADJ
ajrhss-1518	134	28	antiviral	antiviral	ADJ
ajrhss-1518	134	29	drug	drug	NOUN
ajrhss-1518	134	30	.	.	PUNCT
ajrhss-1518	135	1	infectious	infectious	ADJ
ajrhss-1518	135	2	diseases	disease	NOUN
ajrhss-1518	135	3	.	.	PUNCT
ajrhss-1518	136	1	2019;17(4):13	2019;17(4):13	X
ajrhss-1518	136	2	-	-	SYM
ajrhss-1518	136	3	7	7	NUM
ajrhss-1518	136	4	(	(	PUNCT
ajrhss-1518	136	5	in	in	ADP
ajrhss-1518	136	6	russian	russian	NOUN
ajrhss-1518	136	7	)	)	PUNCT
ajrhss-1518	136	8	]	]	PUNCT
ajrhss-1518	136	9	.	.	PUNCT
ajrhss-1518	137	1	doi	doi	NOUN
ajrhss-1518	137	2	:	:	PUNCT
ajrhss-1518	137	3	10.20953/1729	10.20953/1729	NUM
ajrhss-1518	137	4	-	-	SYM
ajrhss-1518	137	5	9225	9225	NUM
ajrhss-1518	137	6	-	-	PUNCT
ajrhss-1518	137	7	2019	2019	NUM
ajrhss-1518	137	8	-	-	PUNCT
ajrhss-1518	137	9	4	4	NUM
ajrhss-1518	137	10	-	-	NUM
ajrhss-1518	137	11	13	13	NUM
ajrhss-1518	137	12	-	-	SYM
ajrhss-1518	137	13	17	17	NUM
ajrhss-1518	137	14	17	17	NUM
ajrhss-1518	137	15	.	.	PUNCT
ajrhss-1518	138	1	облоқулов	облоқулов	PROPN
ajrhss-1518	138	2	,	,	PUNCT
ajrhss-1518	138	3	а	а	PROPN
ajrhss-1518	138	4	.	.	PROPN
ajrhss-1518	138	5	,	,	PUNCT
ajrhss-1518	138	6	&	&	CCONJ
ajrhss-1518	138	7	муҳаммадиева	муҳаммадиева	PROPN
ajrhss-1518	138	8	,	,	PUNCT
ajrhss-1518	138	9	м	м	X
ajrhss-1518	138	10	.	.	PUNCT
ajrhss-1518	138	11	(	(	PUNCT
ajrhss-1518	138	12	2022	2022	NUM
ajrhss-1518	138	13	)	)	PUNCT
ajrhss-1518	138	14	.	.	PUNCT
ajrhss-1518	139	1	клинико	клинико	ADJ
ajrhss-1518	139	2	-	-	PUNCT
ajrhss-1518	139	3	лабораторная	лабораторная	ADJ
ajrhss-1518	139	4	характеристика	характеристика	ADJ
ajrhss-1518	139	5	спонтанного	спонтанного	NOUN
ajrhss-1518	139	6	бактериального	бактериального	NOUN
ajrhss-1518	139	7	перитонита	перитонита	PROPN
ajrhss-1518	139	8	при	при	PROPN
ajrhss-1518	139	9	циррозе	циррозе	PROPN
ajrhss-1518	139	10	печени	печени	PROPN
ajrhss-1518	139	11	вирусной	вирусной	VERB
ajrhss-1518	139	12	этиологиии	этиологиии	ADV
ajrhss-1518	139	13	.	.	PUNCT
ajrhss-1518	140	1	журнал	журнал	NOUN
ajrhss-1518	140	2	вестник	вестник	ADP
ajrhss-1518	140	3	врача	врача	NOUN
ajrhss-1518	140	4	,	,	PUNCT
ajrhss-1518	140	5	1(3	1(3	NUM
ajrhss-1518	140	6	)	)	PUNCT
ajrhss-1518	140	7	,	,	PUNCT
ajrhss-1518	140	8	66–69	66–69	NOUN
ajrhss-1518	140	9	.	.	PUNCT
ajrhss-1518	141	1	извлечено	извлечено	NOUN
ajrhss-1518	141	2	от	от	ADP
ajrhss-1518	141	3	https://inlibrary.uz/index.php/doctors_herald/article/view/2016	https://inlibrary.uz/index.php/doctors_herald/article/view/2016	PROPN
ajrhss-1518	141	4	18	18	NUM
ajrhss-1518	141	5	.	.	PUNCT
ajrhss-1518	141	6	mukhammadieva	mukhammadieva	PROPN
ajrhss-1518	141	7	m.i	m.i	PROPN
ajrhss-1518	141	8	.	.	PROPN
ajrhss-1518	141	9	(	(	PUNCT
ajrhss-1518	141	10	2022	2022	NUM
ajrhss-1518	141	11	)	)	PUNCT
ajrhss-1518	141	12	.	.	PUNCT
ajrhss-1518	142	1	modern	modern	ADJ
ajrhss-1518	142	2	clinical	clinical	ADJ
ajrhss-1518	142	3	and	and	CCONJ
ajrhss-1518	142	4	biochemical	biochemical	ADJ
ajrhss-1518	142	5	characteristics	characteristic	NOUN
ajrhss-1518	142	6	of	of	ADP
ajrhss-1518	142	7	liver	liver	NOUN
ajrhss-1518	142	8	cirrhosis	cirrhosis	NOUN
ajrhss-1518	142	9	patients	patient	NOUN
ajrhss-1518	142	10	of	of	ADP
ajrhss-1518	142	11	viral	viral	ADJ
ajrhss-1518	142	12	etiology	etiology	NOUN
ajrhss-1518	142	13	with	with	ADP
ajrhss-1518	142	14	spontaneous	spontaneous	ADJ
ajrhss-1518	142	15	bacterial	bacterial	ADJ
ajrhss-1518	142	16	peritonitis	peritonitis	NOUN
ajrhss-1518	142	17	//texas	//texas	SYM
ajrhss-1518	142	18	journal	journal	NOUN
ajrhss-1518	142	19	of	of	ADP
ajrhss-1518	142	20	medical	medical	ADJ
ajrhss-1518	142	21	science	science	NOUN
ajrhss-1518	142	22	.	.	PUNCT
ajrhss-1518	143	1	–	–	PUNCT
ajrhss-1518	143	2	2022.p	2022.p	NUM
ajrhss-1518	143	3	.	.	PUNCT
ajrhss-1518	144	1	86	86	NUM
ajrhss-1518	144	2	-	-	SYM
ajrhss-1518	144	3	90	90	NUM
ajrhss-1518	144	4	.	.	NOUN
ajrhss-1518	145	1	19	19	NUM
ajrhss-1518	145	2	.	.	PUNCT
ajrhss-1518	145	3	obloqulov	obloqulov	PROPN
ajrhss-1518	145	4	a	a	DET
ajrhss-1518	145	5	r.	r.	PROPN
ajrhss-1518	145	6	,	,	PUNCT
ajrhss-1518	145	7	aslonova	aslonova	PROPN
ajrhss-1518	145	8	m	m	PROPN
ajrhss-1518	145	9	r.	r.	NOUN
ajrhss-1518	145	10	(	(	PUNCT
ajrhss-1518	145	11	2022	2022	NUM
ajrhss-1518	145	12	)	)	PUNCT
ajrhss-1518	145	13	.	.	PUNCT
ajrhss-1518	146	1	to	to	PART
ajrhss-1518	146	2	indentify	indentify	VERB
ajrhss-1518	146	3	the	the	DET
ajrhss-1518	146	4	calciological	calciological	ADJ
ajrhss-1518	146	5	deficiency	deficiency	NOUN
ajrhss-1518	146	6	that	that	PRON
ajrhss-1518	146	7	occurs	occur	VERB
ajrhss-1518	146	8	against	against	ADP
ajrhss-1518	146	9	the	the	DET
ajrhss-1518	146	10	background	background	NOUN
ajrhss-1518	146	11	of	of	ADP
ajrhss-1518	146	12	helminthiasis	helminthiasis	NOUN
ajrhss-1518	146	13	in	in	ADP
ajrhss-1518	146	14	children//	children//	PROPN
ajrhss-1518	146	15	central	central	ADJ
ajrhss-1518	146	16	asian	asian	ADJ
ajrhss-1518	146	17	journal	journal	NOUN
ajrhss-1518	146	18	of	of	ADP
ajrhss-1518	146	19	medical	medical	ADJ
ajrhss-1518	146	20	and	and	CCONJ
ajrhss-1518	146	21	natural	natural	ADJ
ajrhss-1518	146	22	sciences.–2022.–с	sciences.–2022.–с	PROPN
ajrhss-1518	146	23	.	.	PROPN
ajrhss-1518	146	24	91	91	NUM
ajrhss-1518	146	25	-	-	SYM
ajrhss-1518	146	26	95	95	NUM
ajrhss-1518	146	27	.	.	PUNCT
ajrhss-1518	146	28	20	20	NUM
ajrhss-1518	146	29	.	.	NUM
ajrhss-1518	146	30	деева	деева	NOUN
ajrhss-1518	147	1	э.г	э.г	PROPN
ajrhss-1518	147	2	.	.	PROPN
ajrhss-1518	147	3	,	,	PUNCT
ajrhss-1518	147	4	киселев	киселев	VERB
ajrhss-1518	147	5	о.и	о.и	PROPN
ajrhss-1518	147	6	.	.	PROPN
ajrhss-1518	147	7	,	,	PUNCT
ajrhss-1518	147	8	мельникова	мельникова	PROPN
ajrhss-1518	147	9	т.и	т.и	PROPN
ajrhss-1518	147	10	.	.	PROPN
ajrhss-1518	147	11	,	,	PUNCT
ajrhss-1518	147	12	и	и	PROPN
ajrhss-1518	147	13	др	др	PROPN
ajrhss-1518	147	14	.	.	PROPN
ajrhss-1518	147	15	новый	новый	PROPN
ajrhss-1518	147	16	противовирусный	противовирусный	PROPN
ajrhss-1518	147	17	препарат	препарат	VERB
ajrhss-1518	147	18	«	«	PUNCT
ajrhss-1518	147	19	триазавирин	триазавирин	NOUN
ajrhss-1518	147	20	»	»	PUNCT
ajrhss-1518	147	21	.	.	PUNCT
ajrhss-1518	148	1	результаты	результаты	PROPN
ajrhss-1518	148	2	i	i	PRON
ajrhss-1518	148	3	фазы	фазы	NOUN
ajrhss-1518	148	4	клинического	клинического	NOUN
ajrhss-1518	148	5	исследования	исследования	NOUN
ajrhss-1518	148	6	.	.	PUNCT
ajrhss-1518	149	1	эпидемиология	эпидемиология	VERB
ajrhss-1518	149	2	и	и	PROPN
ajrhss-1518	149	3	инфекционные	инфекционные	ADJ
ajrhss-1518	149	4	болезни	болезни	NOUN
ajrhss-1518	149	5	.	.	PUNCT
ajrhss-1518	150	1	2013;18(5):20	2013;18(5):20	NUM
ajrhss-1518	150	2	-	-	SYM
ajrhss-1518	150	3	6	6	NUM
ajrhss-1518	150	4	[	[	X
ajrhss-1518	150	5	deeva	deeva	ADJ
ajrhss-1518	150	6	eg	eg	NOUN
ajrhss-1518	150	7	,	,	PUNCT
ajrhss-1518	150	8	kiselev	kiselev	PROPN
ajrhss-1518	150	9	li	li	PROPN
ajrhss-1518	150	10	,	,	PUNCT
ajrhss-1518	150	11	melnikova	melnikova	PROPN
ajrhss-1518	150	12	ti	ti	PROPN
ajrhss-1518	150	13	,	,	PUNCT
ajrhss-1518	150	14	et	et	PROPN
ajrhss-1518	150	15	al	al	PROPN
ajrhss-1518	150	16	.	.	PUNCT
ajrhss-1518	151	1	new	new	ADJ
ajrhss-1518	151	2	antiviral	antiviral	ADJ
ajrhss-1518	151	3	drug	drug	NOUN
ajrhss-1518	151	4	triazavirin	triazavirin	PROPN
ajrhss-1518	151	5	.	.	PUNCT
ajrhss-1518	152	1	results	result	NOUN
ajrhss-1518	152	2	of	of	ADP
ajrhss-1518	152	3	phase	phase	NOUN
ajrhss-1518	152	4	1	1	NUM
ajrhss-1518	152	5	clinical	clinical	ADJ
ajrhss-1518	152	6	trial	trial	NOUN
ajrhss-1518	152	7	.	.	PUNCT
ajrhss-1518	153	1	epidemiol	epidemiol	PROPN
ajrhss-1518	153	2	infect	infect	VERB
ajrhss-1518	153	3	dis	dis	PROPN
ajrhss-1518	153	4	.	.	PUNCT
ajrhss-1518	154	1	2013;18(5):20	2013;18(5):20	NUM
ajrhss-1518	154	2	-	-	SYM
ajrhss-1518	154	3	6	6	NUM
ajrhss-1518	154	4	(	(	PUNCT
ajrhss-1518	154	5	in	in	ADP
ajrhss-1518	154	6	russian	russian	NOUN
ajrhss-1518	154	7	)	)	PUNCT
ajrhss-1518	154	8	]	]	PUNCT
ajrhss-1518	154	9	.	.	PUNCT
ajrhss-1518	155	1	doi	doi	NOUN
ajrhss-1518	155	2	:	:	PUNCT
ajrhss-1518	155	3	10.17816	10.17816	NUM
ajrhss-1518	155	4	/	/	SYM
ajrhss-1518	155	5	eid40768	eid40768	NOUN
ajrhss-1518	155	6	21	21	NUM
ajrhss-1518	155	7	.	.	PUNCT
ajrhss-1518	156	1	mukhtorova	mukhtorova	PROPN
ajrhss-1518	156	2	shokhida	shokhida	PROPN
ajrhss-1518	156	3	abdulloevna	abdulloevna	VERB
ajrhss-1518	156	4	.	.	PUNCT
ajrhss-1518	157	1	(	(	PUNCT
ajrhss-1518	157	2	2023	2023	NUM
ajrhss-1518	157	3	)	)	PUNCT
ajrhss-1518	157	4	.	.	PUNCT
ajrhss-1518	158	1	characteristic	characteristic	ADJ
ajrhss-1518	158	2	features	feature	NOUN
ajrhss-1518	158	3	of	of	ADP
ajrhss-1518	158	4	the	the	DET
ajrhss-1518	158	5	course	course	NOUN
ajrhss-1518	158	6	of	of	ADP
ajrhss-1518	158	7	citomegalovirus	citomegalovirus	ADJ
ajrhss-1518	158	8	infection	infection	NOUN
ajrhss-1518	158	9	in	in	ADP
ajrhss-1518	158	10	children	child	NOUN
ajrhss-1518	158	11	.	.	PUNCT
ajrhss-1518	159	1	galaxy	galaxy	PROPN
ajrhss-1518	159	2	international	international	ADJ
ajrhss-1518	159	3	interdisciplinary	interdisciplinary	ADJ
ajrhss-1518	159	4	research	research	NOUN
ajrhss-1518	159	5	journal	journal	NOUN
ajrhss-1518	159	6	,	,	PUNCT
ajrhss-1518	159	7	11(4	11(4	NUM
ajrhss-1518	159	8	)	)	PUNCT
ajrhss-1518	159	9	,	,	PUNCT
ajrhss-1518	159	10	484–487	484–487	NUM
ajrhss-1518	159	11	.	.	PUNCT
ajrhss-1518	159	12	retrieved	retrieve	VERB
ajrhss-1518	159	13	from	from	ADP
ajrhss-1518	159	14	https://giirj.com/index.php/giirj/article/view/5150	https://giirj.com/index.php/giirj/article/view/5150	NOUN
ajrhss-1518	159	15	..	..	PROPN
ajrhss-1518	159	16	22	22	NUM
ajrhss-1518	159	17	.	.	PUNCT
ajrhss-1518	160	1	raximovich	raximovich	ADV
ajrhss-1518	160	2	,	,	PUNCT
ajrhss-1518	160	3	o.	o.	NOUN
ajrhss-1518	160	4	a.	a.	PROPN
ajrhss-1518	160	5	,	,	PUNCT
ajrhss-1518	160	6	sadilloyevna	sadilloyevna	NOUN
ajrhss-1518	160	7	,	,	PUNCT
ajrhss-1518	160	8	j.	j.	PROPN
ajrhss-1518	160	9	a.	a.	PROPN
ajrhss-1518	160	10	,	,	PUNCT
ajrhss-1518	160	11	abdulloyevna	abdulloyevna	NOUN
ajrhss-1518	160	12	,	,	PUNCT
ajrhss-1518	160	13	m.	m.	NOUN
ajrhss-1518	160	14	s.	s.	PROPN
ajrhss-1518	160	15	,	,	PUNCT
ajrhss-1518	160	16	&	&	CCONJ
ajrhss-1518	160	17	farxodovich	farxodovich	PROPN
ajrhss-1518	160	18	,	,	PUNCT
ajrhss-1518	160	19	r.	r.	PROPN
ajrhss-1518	160	20	f.	f.	PROPN
ajrhss-1518	160	21	(	(	PUNCT
ajrhss-1518	160	22	2022	2022	NUM
ajrhss-1518	160	23	)	)	PUNCT
ajrhss-1518	160	24	.	.	PUNCT
ajrhss-1518	161	1	microbiological	microbiological	ADJ
ajrhss-1518	161	2	indicators	indicator	NOUN
ajrhss-1518	161	3	of	of	ADP
ajrhss-1518	161	4	patients	patient	NOUN
ajrhss-1518	161	5	with	with	ADP
ajrhss-1518	161	6	confirmed	confirm	VERB
ajrhss-1518	161	7	sars	sar	NOUN
ajrhss-1518	161	8	-	-	PUNCT
ajrhss-1518	161	9	cov-2	cov-2	PART
ajrhss-1518	161	10	infection	infection	NOUN
ajrhss-1518	161	11	.	.	PUNCT
ajrhss-1518	162	1	central	central	ADJ
ajrhss-1518	162	2	asian	asian	ADJ
ajrhss-1518	162	3	journal	journal	NOUN
ajrhss-1518	162	4	of	of	ADP
ajrhss-1518	162	5	medical	medical	ADJ
ajrhss-1518	162	6	and	and	CCONJ
ajrhss-1518	162	7	natural	natural	ADJ
ajrhss-1518	162	8	science	science	NOUN
ajrhss-1518	162	9	,	,	PUNCT
ajrhss-1518	162	10	3(2	3(2	NUM
ajrhss-1518	162	11	)	)	PUNCT
ajrhss-1518	162	12	,	,	PUNCT
ajrhss-1518	162	13	289	289	NUM
ajrhss-1518	162	14	-	-	SYM
ajrhss-1518	162	15	294	294	NUM
ajrhss-1518	162	16	.	.	PUNCT
ajrhss-1518	163	1	https://doi.org/10.17605/osf.io/9cfp6	https://doi.org/10.17605/osf.io/9cfp6	PUNCT
ajrhss-1518	164	1	https://doi.org/10.20953/1729-9225-2019-4-13-17	https://doi.org/10.20953/1729-9225-2019-4-13-17	ADV
ajrhss-1518	164	2	https://inlibrary.uz/index.php/doctors_herald/article/view/2016	https://inlibrary.uz/index.php/doctors_herald/article/view/2016	PROPN
ajrhss-1518	164	3	https://doi.org/10.17816/eid40768	https://doi.org/10.17816/eid40768	NOUN
ajrhss-1518	164	4	https://giirj.com/index.php/giirj/article/view/5150	https://giirj.com/index.php/giirj/article/view/5150	NOUN